nctId,type,statement
NCT00772174,Exclusion,"Required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including: other oral antidiabetic drugs than metformin or with insulin in the 3 months preceding study entry. Fibrates Rifampicin"
NCT00762957,Exclusion,"Took any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may have interfered with evaluation of the study medication, including: Insulin Oral antidiabetics including sulfonylureas and alpha-glucosidase inhibitors Systemic corticosteroids Warfarin Rifampin St. John's Wort. Thiazolidinediones Peroxisome proliferator-activated receptor agonists Nicotinic Acid Fibrates"
NCT06473662,Exclusion,"History of diabetic ketoacidosis requiring hospitalization within 6 months prior to enrolment, case of proliferative retinopathy or advanced neuropathy Subject having any of the following laboratory results at screening Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73
m2 Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) >3 times of upper limit normal"
NCT04373265,Exclusion,"Treated with the following prior to the first dose of relacorilant: Any investigational product, systemic anticancer therapy, or radiation therapy within 21 days Antibodies or anticancer vaccines within 60 days Mifepristone or other GR antagonists within 5 half-lives of these medications Adrenostatic medications within 5 half-lives of these medications"
NCT05369065,Exclusion,"Hepatic decompensation defined as the presence of any of the following: Serum albumin less than 3.5 g/dL International normalization ratio (INR) greater than 1.4 (unless due to therapeutic anticoagulants) Total bilirubin greater than 2 mg/dL with the exception of Gilbert syndrome History of esophageal varices, ascites, or hepatic encephalopathy"
NCT01462266,Inclusion,"has one of the following criteria: diagnosed with diabetes after age 40 years and insulin therapy was initiated at least 3 years following diagnosis if diagnosed with diabetes under age 40 years or insulin started earlier than 3 years after diagnosis, has a fasting C-peptide greater than 0.7 ng/mL"
NCT03811548,Exclusion,"Any laboratory test indicators meet the following standards: fasting plasma glucose ≥ 15 mmol/L aspartate aminotransferase, alanine aminotransferase levels > 3 times the upper limit of normal (ULN); total bilirubin > 1.5 times ULN hemoglobin < 100 g/L eGFR < 60 mL/min/1.73m2 fasting triglycerides > 5.64 mmol/L (500 mg/dL)"
NCT00596427,Inclusion,"Male or Female Females of childbearing potential who are on approved birth control method: oral, injectable, or implantable hormonal contraceptives; intrauterine device; diaphragm plus spermicide or female condom plus spermicide Females of non-childbearing potential: hysterectomy, tubal ligation 6 months prior screening or post-menopausal for at least 1 year"
NCT00770835,Inclusion,"Has one or more cardiovascular comorbidities as follows: stable angina pectoris previous (greater than three months) transient ischemic attack, cerebrovascular accident or carotid atherosclerosis as assessed by bilateral carotid artery ultrasonography peripheral vascular complications documented by a history of claudication or rest pain, ultrasonography or angiography."
NCT02974816,Inclusion,"If female is of childbearing potential, is practicing one of the following methods of birth control (and will continue through the duration of the study): Condoms, sponge, diaphragm, or intrauterine device; Oral or parenteral contraceptives for 3 months prior to screening visit; Vasectomized partner; Total abstinence from sexual intercourse"
NCT02689362,Exclusion,"Concomitant use of drugs or foods that interfere with the CYP3A4 pathway of liver metabolism including, but not limited to: Inhibitors: antibacterial agents (erythromycin), antifungals (itraconazole, ketoconazole), antivirals (ritonavir, saquinavir, amprenavir, indinavir, nelfinavir), H2 receptor antagonists (cimetidine) and grapefruit juice; Inducers: dexamethasone, rifampin and anticonvulsants (phenytoin, phenobarbital, carbamazepine)"
NCT00487240,Inclusion,"As determined by the investigator, are capable and willing to do the following: perform self monitoring of blood glucose (SMBG), complete patient diaries as required for this protocol, use the insulin injection device(s) according to the instructions provided, are receptive to diabetes education, comply with the required study visits."
NCT03289494,Exclusion,General criteria: Patient under legal protection measure Patient deprived of liberty by a court or an administrative decision Patient currently participating in another study or being in the exclusion period of another study Volunteer that exceed the financial compensation allowed per year for participating in research programs
NCT01018017,Exclusion,"Renal or liver impairment, defined as: Serum creatinine level of ≥ 1.4 mg/dL for females and ≥ 1.5 mg/dL for males AST and ALT ≥ 2xULN alkaline phosphatase and bilirubin > 1.5xULN (an isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin is <35%)"
NCT01868646,Exclusion,Heart rhythm disorder: II-III atrioventricular block; sick sinus syndrome; long QT interval syndrome; complete left bundle branch block; block of 2/3 bundle branches; WPW syndrome; ventricular arrhythmia of III grade according Laun-Wolf; paroxysmal supraventricular tachycardia; paroxysmal/recurrent ventricular tachycardia; atrial flutter and fibrillation; ventricular flutter and fibrillation; heart pacemaker implant.
NCT03091712,Inclusion,"If female is of childbearing potential, is practicing one of the following methods of birth control (and will continue through the duration of the study): Condoms, sponge, diaphragm, or intrauterine device; Oral or parenteral contraceptives for 3 months prior to screening visit; Vasectomized partner; Total abstinence from sexual intercourse"
NCT05834868,Inclusion,"Treated with stable insulin regimen as follow for at least 3 months with or without oral antidiabetic drug: Basal insulin (neutral protamine Hagedorn [NPH] insulin, insulin glargine, insulin degludec, insulin detemir) in combination with at least 1 prandial injection of bolus insulin. Premixed insulin at least twice daily."
NCT02954601,Exclusion,"Any clinically significant ECG abnormality at Screening or cardiovascular disease.
Clinically significant cardiovascular disease will include: History of stroke, transient ischemic attack, or myocardial infarction within 6 months prior to Screening, History of or currently have New York Heart Associate Class II-IV heart failure prior to Screening, or"
NCT06152042,Inclusion,Diagnosed with stage 3 T1D within the following timeframes: Part 1 Cohort 1: Participants diagnosed within 3 years prior to screening. Part 1 Cohort 2: Participants diagnosed between 3 to 15 years prior to screening Part 2 : Participants diagnosed within 15 years prior to screening.
NCT04515849,Exclusion,Significant hepatic disease (except for non-alcoholic steatohepatitis or nonalcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results: Aspartate transaminase (AST) ≥ 3 × upper limit of normal (ULN) Alanine transaminase (ALT) ≥ 3 × ULN Total bilirubin ≥ 2 × ULN
NCT03344341,Exclusion,Any of the following cardiovascular diseases within 6 months of the enrollment visit: Myocardial infarction; Cardiac surgery or revascularization (coronary artery bypass graft/percutaneous transluminal coronary angioplasty); Unstable angina; Congestive heart failure New York Heart Association Class III or IV; Transient ischemic attack or significant cerebrovascular disease.
NCT03310749,Exclusion,Subjects who show one of the following results at screening test: Exceeds 1.5 times the upper limit of the normal range of blood AST (SGOT) and ALT (SGPT) The creatinine clearance calculated by Cockcroft-Gault equation is below 80 mL/min. QTc > 450 ms in ECG or clinically significant abnormal rhythm
NCT00879970,Inclusion,"Age ≥ 55 years and evidence of subclinical vascular disease defined as ≥1 of: microalbuminuria or proteinuria history of treated or untreated hypertension with left ventricular hypertrophy by electrocardiogram (ECG) or echocardiogram 50% stenosis on any imaging of coronary, carotid or lower extremity arteries ankle/brachial index <0.9 OR"
NCT04484779,Inclusion,"Using insulin injection regimen of basal/bolus or basal only for 3 months prior to screening, which includes: for bolus insulin (U-100) - a rapid-acting insulin analog (glulisine, lispro, or aspart). for basal insulin - degludec (U-100 or U-200), detemir (U-100), or glargine (U- 100 or U-300)."
NCT02512523,Inclusion,"Patient has adequate renal and hepatic function at screening as defined by the following clinical chemistry results: (male) Serum creatinine <1.5 × upper limit of normal (ULN), (female) Serum creatinine <1.4 × upper limit of normal (ULN), Serum alanine aminotransferase <2.5 × ULN Serum aspartate aminotransferase <2.5 × ULN"
NCT05275400,Inclusion,"Have been treated with one of the following stable insulin regimens at least 90 days prior to screening: once daily U100 or U200 of insulin degludec once daily U100 or U300 of insulin glargine once or twice daily U100 of insulin detemir, or once or twice daily human insulin NPH"
NCT02784275,Exclusion,"Subjects who have any of the following conditions related to gastrointestinal disease: Chronic hepatitis or cirrhosis. Episode of alcoholic hepatitis or alcoholic pancreatitis in the past 2 months. Inflammatory bowel disease requiring treatment in the past 12 months. Significant abdominal surgery (e.g., gastrectomy, gastric bypass) in the past 2 months."
NCT04865770,Inclusion,"Depending on biopsy/non-biopsy population: For subjects in the non-biopsy population: Serum creatinine-based eGFR greater than or equal to 30 and below or equal to 75 mL/min/1.73
m^2(CKD-EPI). For subjects in the biopsy sub-population: Serum creatinine-based eGFR greater than or equal to 40 and below or equal to 75 mL/min/1.73
m^2(CKD-EPI)."
NCT06151964,Exclusion,Use of any of the following medicinal products: Use of systemic corticosteroids within 28 days prior to screening. Use of compounds known to prolong the QTc interval. Use of any herbal preparations or medicinal products licensed for control of body weight or appetite within 3 months prior to screening.
NCT05803421,Inclusion,"Have increased risk for cardiovascular (CV) events due to: Coronary heart disease Peripheral arterial disease, presumed to be of atherosclerotic origin Cerebrovascular disease, presumed to be of atherosclerotic origin Chronic kidney disease (CKD) Congestive heart failure (CHF) New York Heart Association (NYHA) functional classification II to III"
NCT02082184,Inclusion,"Their insulin management must be one of the following; an injection regimen of prandial insulin at least once daily, or, prandial insulin at least once daily plus basal insulin at least once daily, or, continuous subcutaneous insulin infusion (CSII) with no plans to change during the study."
NCT04047537,Inclusion,"If female, must meet all the following criteria: Not pregnant or breastfeeding If of childbearing potential (including peri-menopausal women who have had a menstrual period within one year) must practice and be willing to continue to practice appropriate birth control during the entire duration of the study"
NCT03745937,Exclusion,Significant hepatic disease (except for nonalcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results at screening: Aspartate transaminase (AST) >= 3 × ULN Alanine transaminase (ALT) >= 3 × ULN Total bilirubin (TBL) >= 2 × ULN
NCT03138356,Inclusion,"For inclusion in the study subjects should fulfill the following criteria: Provision of signed and dated, written informed consent prior to any study specific procedures. Healthy male and/or female subjects aged 18 to 55 years with suitable veins for cannulation or repeated venipuncture. Female subject must either:"
NCT04150107,Inclusion,"Females who are not of childbearing potential are defined as: post-menopausal (defined as at least 12 months with no menses in women ≥45 years of age) or has had a hysterectomy and/or bilateral oophorectomy, or had bilateral tubal ligation or occlusion at least 6 weeks prior to Screening"
NCT03387683,Exclusion,"Any of the following cardiovascular diseases known within 3 months prior to signing the consent at enrolment: Atrial fibrillation, or other unstable or severe arrhythmia affecting heart function Unstable heart failure or any heart failure with NYHA class III and IV Significant valvular disease Significant peripheral artery disease"
NCT05363761,Exclusion,"Hepatic decompensation defined as the presence of any of the following: Serum albumin less than 3.5 g/dL International normalization ratio (INR) greater than 1.4 (unless due to therapeutic anticoagulants) Total bilirubin greater than 2 mg/dL with the exception of Gilbert syndrome History of esophageal varices, ascites, or hepatic encephalopathy"
NCT03851432,Exclusion,"Any laboratory test indicators meet the following standards: fasting plasma glucose ≥ 15 mmol/L aspartate aminotransferase, alanine aminotransferase levels > 3 times the upper limit of normal (ULN); total bilirubin > 1.5 times ULN hemoglobin < 100 g/L eGFR < 60 mL/min/1.73m2 fasting triglycerides > 5.64 mmol/L (500 mg/dL)"
NCT03550378,Exclusion,Significant hepatic disease (except for non-alcoholic steatohepatitis or nonalcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results: Aspartate transaminase (AST) ≥ 3 × upper limit of normal (ULN) Alanine transaminase (ALT) ≥ 3 × ULN Total bilirubin ≥ 2 × ULN
NCT02561078,Inclusion,"Current TDD >200 but ≤600 units of non U-500R insulin (MDI or CSII) and/or U-500R by MDI with syringe and vial for ≥3 months at entry. If TDD of U-500R and other insulins are combined, then insulin other than U-500R not to exceed 25% of TDD."
NCT02791490,Exclusion,"Has human immunodeficiency virus (HIV) with AIDS related complications, or has not been on a stable anti-retroviral regimen for >6 months, or has progressive disease, or using agents associated with glucose intolerance such as nucleoside reverse transcriptase inhibitors (NRTIs) such as azidothymidine (AZT), didanosine (ddI), and stavudine (d4T)."
NCT01551446,Exclusion,"Recently active cardiovascular disease defined as: Unstable angina pectoris within 12 weeks before Study Day 1; Myocardial infarction, coronary artery bypass graft surgery, or percutaneous transluminal coronary angioplasty/stent within 12 weeks before Study Day 1; Cerebrovascular accident, including transient ischemic attack within 12 weeks before Study Day 1;"
NCT01582451,Exclusion,Lipid-lowering medication: Are using or have used any of the following: niacin preparations as a lipid-lowering medication and/or bile acid sequestrants within 90 days prior to screening or lipid-lowering medication at a dose that has not been stable for at least 90 days prior to screening
NCT01576887,Exclusion,"History of recently active cardiovascular disease defined as: Unstable angina pectoris within 12 weeks before study randomization Myocardial infarction, coronary artery bypass graft surgery, or percutaneous transluminal coronary angioplasty/stent within 12 weeks before study randomization Cerebrovascular accident, including transient ischemic attack within 12 weeks before study randomization"
NCT02079805,Exclusion,"Past or current history of any of the following cardiovascular diseases. Cardiac valve stenosis Angina pectoris requiring medication Congestive cardiac failure requiring medication Arrhythmia requiring medication (e.g., paroxysmal atrial fibrillation, severe bradycardia, torsade de pointes, and ventricular fibrillation) Arteriosclerosis obliterans with intermittent claudication or other symptoms"
NCT04285554,Inclusion,"Type 2 diabetes diagnosis meeting the following criteria: HbA1c > 7.0% and ≤ 9.0% (53 mmol/mol - 75 mmol/mol), AND On at least two anti-diabetic medications; one at the highest tolerated dose with no changes in medication dose in the 12 weeks prior to the first screening visit"
NCT04285554,Exclusion,"Hepatic decompensation defined as the presence of any of the following: Serum albumin less than 3.5 g/dL International normalized ratio (INR) greater than 1.4 (unless due to therapeutic anticoagulants) Total bilirubin greater than 2 mg/dL with the exception of Gilbert syndrome History of esophageal varices, ascites, or hepatic encephalopathy"
NCT04350463,Exclusion,"Subject has previous SARS-CoV-2 infection either suspected or confirmed within 4 weeks prior to screening. Acute symptoms must have resolved and based on Investigator assessment in consultation with the Medical Monitor, there are no sequelae that would place the subject at a higher risk of receiving investigational treatment."
NCT00157196,Inclusion,"Primary therapy should be a minimum of 2 cycles of Platinum-based first-line chemotherapy, given concurrent with thoracic radiation.
The combined modality should consist of either: induction (2 cycles) chemotherapy followed by concurrent chemo-radiation therapy; or concurrent chemo-radiation therapy followed by 2 cycles of consolidation chemotherapy; or concurrent chemoradiation therapy alone"
NCT01853826,Exclusion,"radiotherapy within 14 days prior to drug administration, except as follows: Palliative radiation to organs other than chest may be allowed up to 2 weeks prior to drug administration, and Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling."
NCT01803282,Inclusion,Part B: Breast Cancer Histologically or cytologically confirmed metastatic breast cancer Radiographically measureable disease Previous hormonal therapy for metastatic breast cancer or cytotoxic adjuvant chemotherapy is allowed Treatment with weekly single-agent paclitaxel is appropriate in the opinion of the treating physician HER-2 negative tumor (primary tumor or metastatic lesion)
NCT02358473,Exclusion,"History of second primary cancer within the past 5 years, with the exception of: Curatively resected non-melanomatous skin cancer; Curatively treated cervical intraepithelial neoplasia or prostate carcinoma with current prostate specific antigen (PSA) < 0.01 ng/mL; or Curatively treated ductal carcinoma in situ of the breast;"
NCT02044380,Exclusion,"Radiotherapy within 28 days prior to drug administration, except as follows: Palliative radiation to organs other than chest may be allowed up to 2 weeks prior to drug administration, and Single dose palliative treatment for symptomatic metastases outside above allowance to be discussed with sponsor prior to enrolling"
NCT03157089,Exclusion,"Previous or concomitant malignancies at other sites than the lung, except: Effectively treated non-melanoma skin cancers; Effectively treated carcinoma in situ of the cervix; Effectively treated ductal carcinoma in situ; Other effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured."
NCT02082210,Exclusion,"For Part B4 (non-small cell lung cancer) only: The participant has radiologically documented evidence of major blood vessel invasion or encasement by cancer Participants with a history of gross hemoptysis within 2 months prior to study treatment The participant has radiographic evidence of intratumor cavitation, regardless of tumor histology"
NCT01970540,Inclusion,"Patients with a histologically/cytologically confirmed diagnosis of advanced disease of any of the following tumors: Breast cancer Soft-tissue sarcoma Primary bone sarcomas. Gynecologic tumors (endometrial adenocarcinomas, epithelial ovarian cancer...) Hepatocellular carcinoma Gastroenteropancreatic neuroendocrine tumors Small cell lung cancer (SCLC) Gastric cancer Bladder cancer Adenocarcinoma of unknown primary site"
NCT01853878,Exclusion,"The patient has received any anti-cancer specific treatment, including radiotherapy, immunotherapy, hormonal therapy, chemotherapy or neo-adjuvant chemotherapy, except for: Administration of adjuvant platinum-based doublet chemotherapy for the treatment of the current NSCLC allowed between surgery and randomization. Treatment of previous malignancies as allowed by the protocol."
NCT04902885,Inclusion,"Histologically or cytologically confirmed extensive stage small cell lung cancer (ES-SCLC): Patients scheduled to receive carboplatin plus etoposide regimen: no prior systemic therapy (eg, chemotherapy or combined with immunotherapy); Patients scheduled to receive topotecan regimen: previously received 1/2 lines of chemotherapy or combined immunotherapy but not topotecan."
NCT01523587,Exclusion,"Female patients of childbearing potential (see Section 4.2.3.3)
who: are nursing or are pregnant or are not using an acceptable method of birth control, or do not plan to continue using this method throughout the study and/or do not agree to submit to pregnancy testing required by this protocol."
NCT01953913,Exclusion,"radiotherapy within 4 weeks prior to drug administration except as follows: palliative radiation to organs other than chest may be allowed up to 2 weeks prior to drug administration, and single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling."
NCT01953913,Exclusion,"childbearing potential (see Section 4.2.3)
who: are nursing or are pregnant or are not using an acceptable method of birth control, or do not plan to continue using this method throughout the trial and/or do not agree to submit to pregnancy testing required by this protocol"
NCT01139775,Inclusion,Phase 2 portion: Have a histological diagnosis of NSCLC other than predominantly squamous cell histology that is classified as Stage IV according to the 7th edition of the AJCC classification Eligible for a first line of palliative treatment with a platinum doublet Have archived or fresh tumor tissue (not cytology)
NCT03310619,Exclusion,Prior treatment with the combination agent from the assigned arm: Anti PD-1 or PD-L1 (Arm A and E) CC-122 (Arm B) CC-220 (Arm C) Prior treatment with ibrutinib is not exclusionary for subjects on any study arm Anti LAG-3 targeted agent (Arm E) CC-99282 (Arm F)
NCT03976375,Inclusion,Has progressive disease (PD) on treatment with one prior anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) monoclonal antibody (mAb) administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies. Retreatment with the same anti-PD-L1/PD-L1 mAb is acceptable in the overall course of treatment
NCT01877083,Inclusion,"Adequate bone marrow function, defined as: Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L (greater than or equal to 1500/mm^3) Hemoglobin (Hb) greater than or equal 8.5 g/dL Platelet count greater than or equal 75 x 10^9/L (greater than or equal 75,000/mm^3)"
NCT02020577,Exclusion,Female patients of childbearing potential who: are nursing or are pregnant or are not using an acceptable method of birth control or do not plan to continue using this method throughout the study and/or do not agree to submit to pregnancy testing required by this protocol.
NCT05205941,Exclusion,"Haematology, biochemistry or urinalysis results that are outside of the laboratory normal reference ranges and are either: considered clinically significant by the Principal Investigator or delegate; OR considered not clinically significant by the Principal Investigator or delegate but are also outside of Sponsor-approved clinically acceptable laboratory ranges"
NCT03462615,Exclusion,"Women meeting any of the following exclusion criteria at screening will be excluded from study participation: History of malaria or antimalarial drugs used in the last three months, as recalled or documented in health record Presence of severe malaria as defined by WHO guidelines at the moment of recruitment."
NCT02389439,Exclusion,"Known history or evidence of clinically significant disorders, such as: Known active Hepatitis A, e.g. by detection of anti HAV-IgM. Known hepatitis B surface antigen (HBsAg) carrier. Known hepatitis C antibody (HCV Ab). Liver function tests (AST/ALT levels) more than 2.5 times the upper limit of normal range."
NCT00935623,Exclusion,"Acute disease at the time of enrollment Acute disease is defined as the presence of a moderate or severe illness with or without fever; Challenge can be administered to persons with a minor illness, such as diarrhea or mild upper respiratory infection without fever (i.e., oral temperature < 38°C/100.4°F);"
NCT05223933,Inclusion,"Inclusion criteria in community: Fokontany in rural communes of Mananjary district (fokontany level of safety, accessibility by the study teams, and phone network availability was assessed). Agreement of the chief of Fokontany for the participation of his fokontany in the study Fokontany with at least 1,000 inhabitants"
NCT04201431,Inclusion,Answer all questions on the informed consent quiz correctly at first or second attempt Female volunteers are required to use a highly effective form of contraception during the course of the study as malaria challenge could pose a serious risk to both maternal health and the unborn foetus.
NCT02511054,Exclusion,"History of: Sickle cell disease, sickle cell trait, or other hemoglobinopathies Splenectomy or functional asplenia Systemic anaphylaxis Any allergic reactions to study drugs Documented history of chronic or active neurologic disease (including seizures, uncontrolled migraine headaches) Psoriasis or porphyria Ocular diseases including retinopathy or visual field defects"
NCT04241705,Inclusion,For Kebeles: Kebeles in East Hararghe Zone targeted for implementation of elimination activities by the Ethiopian Federal Ministry of Health where there is ongoing PMI-supported malaria surveillance; Kebeles with reported API between 1 and 50; Kebeles in malarious districts with comparable optimization of malaria control interventions.
NCT01434381,Exclusion,"Severe asthma.
This will be defined as: Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past 2 years, or that requires the use of oral or parenteral corticosteroids. Clinically significant reactive airway disease that does not respond to bronchodilators."
NCT00422084,Inclusion,"Presence of acute uncomplicated P. falciparum mono-infection confirmed by: Fever, as defined by axillary/tympanic temperature ≥ 37.5°C or oral/rectal temperature ≥ 38°C, or documented history of fever in the previous 24 hours and, Positive microscopy of P. falciparum with parasite density between 1,000 and 100,000 asexual parasite count/μl of blood."
NCT03780712,Inclusion,Child born from mothers having one of the following criteria before delivery will be included in this study: Spontaneous preterm delivery (<37 weeks of gestation time) Foul smelling / with meconium / colored / bloody amniotic liquid Rupture of membranes > 18 hours Maternal fever at delivery Vaginal infection
NCT07060508,Inclusion,Females of childbearing potential must be willing to use reliable contraception from 21 days prior to study Day 0 through the final study visit as described below. Reliable methods of birth control include 1 of the following: confirmed pharmacologic contraceptives via parenteral delivery or intrauterine or implantable device.
NCT03304704,Inclusion,PARASITE SURVEILLANCE COHORT 6 months to 65 years of age Known resident of Bancoumana or the surrounding villages Willingness to allow stored laboratory specimens to be used for future research Acceptance and signature of the written informed consent and the assent for children aged 12-17 years
NCT02554799,Inclusion,Females must be of non-childbearing potential: Natural (spontaneous) post-menopausal defined (amenorrheic for at least 12 months without an alternative medical cause with a screening follicle stimulating hormone level >25IU/L (for post-menopause). Premenopausal with irreversible surgical sterilization by hysterectomy and/or bilateral oophorectomy or salpingectomy at least 6 months before screening
NCT02773979,Exclusion,Active neoplastic disease*. Subjects with a history of malignancy may be included if treated by surgical excision or if treated by chemotherapy or radiation therapy and has been observed for a period that in the investigator's estimation provides a reasonable assurance of sustained cure (not less than 36 months).
NCT02773979,Exclusion,A screening ECG with abnormalities consistent with underlying heart disease.* Pathologic Q waves and significant ST-T wave changes; left ventricular hypertrophy; any non-sinus rhythm excluding isolated premature atrial or ventricular contractions; right or left bundle branch block; QT/QTc interval > 450 ms; or advanced (secondary or tertiary) A-V heart block.
NCT02773979,Exclusion,"Is using or intends to use a medication that is cross-reactive with CQ** or atovaquone and proguanil, such as cimetidine or metoclopramide, during the study period. Antacids and kaolin can be administered at least 4 hours from intake of chloroquine. Does not apply to infectivity controls"
NCT02083380,Inclusion,"Presence of mono-infection of P. falciparum with: Fever, as defined by axillary temperature ≥ 37.5°C or oral/rectal/tympanic temperature ≥ 38°C, or history of fever in the previous 24 hours (history of fever must be documented) and, Microscopically confirmed parasite infection, in range 1,000 to 100,000 asexual parasites /µL of blood."
NCT00666380,Exclusion,"Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or abnormal baseline laboratory screening tests ALT above normal range Creatinine above normal range Hemoglobin below normal range Platelet count below normal range Total white cell count below normal range"
NCT00298610,Exclusion,"Laboratory evidence or history of significant cardiovascular, liver or renal functional abnormality, which in the opinion of the investigator would place them at increased risk.
Specifically, the following will serve as exclusionary lab values: Creatinine >1.4 x ULN (>2.0 mg/dL) Glucose <LLN (65mg/dL) AST, ALT >3x ULN (120 U/L)"
NCT00487916,Exclusion,"Severe asthma.
This will be defined as: Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past two years or that requires the use of oral or parenteral corticosteroids. Clinically significant reactive airway disease that does not respond to bronchodilators."
NCT05095272,Exclusion,Vital signs taken after 5 minutes of resting in seated or supine position that fall outside the following ranges: Systolic blood pressure <=90 mm Hg or >=140 mm Hg. Diastolic blood pressure <=50 mm Hg or >=90 mm Hg. Heart rate <=40 bpm or >=100 bpm.
NCT02458092,Inclusion,• A male or non-lactating female 18 to 50 years of age (inclusive) at the time of screening Free of significant health problems as established by medical history and clinical examination before entering into the study Available to participate for duration of study (approximately seven months)
NCT04327310,Exclusion,"Abnormal vital signs at Screening (supine and standing) and on Day 1 (Parts A and C) or pre-inoculation on Day 8 (Part B) (supine), defined as any of the following: Systolic blood pressure <90 or >140 mmHg. Diastolic blood pressure <40 or >90 mmHg. Pulse rate <40 or >100 bpm."
NCT00414336,Exclusion,"Severe asthma.
This will be defined as: Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past two years or that requires the use of oral or parenteral corticosteroids; Clinically significant reactive airway disease that does not respond to bronchodilators."
NCT06069544,Exclusion,"The following diseases associated with immune dysregulation: Primary immunodeficiencies. History of solid organ or bone marrow transplantation. Asplenia: any condition resulting in the absence of a functional spleen. Currently existing or history of autoimmune disease including and not limited to thyroid autoimmune disease, multiple sclerosis, psoriasis, etc."
NCT05581641,Exclusion,"The following diseases associated with immune dysregulation: Primary immunodeficiencies. History of solid organ or bone marrow transplantation. Asplenia: any condition resulting in the absence of a functional spleen. Currently existing or history of autoimmune disease including and not limited to thyroid autoimmune disease, multiple sclerosis, psoriasis, etc."
NCT01713621,Inclusion,"Presence of mono-infection of P. falciparum confirmed by: Fever, as defined by axillary temperature ≥ 37.5°C or oral/rectal/tympanic temperature ≥ 38°C, or history of fever in the previous 24 hours (history of fever must be documented) and, Microscopically confirmed parasite infection: 1,000 to 75,000 asexual parasite count/µL blood."
NCT00889616,Exclusion,"Severe asthma.
This will be defined as: Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past 2 years, or that requires the use of oral or parenteral corticosteroids Clinically significant reactive airway disease that does not respond to bronchodilators"
NCT00541385,Inclusion,"Presence of acute uncomplicated P. falciparum mono-infection confirmed by: Fever, as defined by axillary temperature ≥37.5°C or oral/tympanic/rectal temperature ≥38°C, or documented history of fever in the previous 24 hours and, Positive microscopy of P. falciparum with parasite density between 1,000 and 200,000 asexual parasite count/µl of blood."
NCT00772174,Exclusion,"Required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including: other oral antidiabetic drugs than metformin or with insulin in the 3 months preceding study entry. Fibrates Rifampicin"
NCT00762957,Exclusion,"Took any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may have interfered with evaluation of the study medication, including: Insulin Oral antidiabetics including sulfonylureas and alpha-glucosidase inhibitors Systemic corticosteroids Warfarin Rifampin St. John's Wort. Thiazolidinediones Peroxisome proliferator-activated receptor agonists Nicotinic Acid Fibrates"
NCT06451757,Inclusion,"Presence of chronic fatigue (not attributable to other etiologies than PMD): Patient self-reported chronic fatigue for at least 3 months prior to the Screening Visit and recorded in the clinical patient files; AND Presence of fatigue (raw total score >22), assessed by Neuro-QoL SFv1-F at Screening."
NCT06473662,Exclusion,"History of diabetic ketoacidosis requiring hospitalization within 6 months prior to enrolment, case of proliferative retinopathy or advanced neuropathy Subject having any of the following laboratory results at screening Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73
m2 Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) >3 times of upper limit normal"
NCT04373265,Exclusion,"Treated with the following prior to the first dose of relacorilant: Any investigational product, systemic anticancer therapy, or radiation therapy within 21 days Antibodies or anticancer vaccines within 60 days Mifepristone or other GR antagonists within 5 half-lives of these medications Adrenostatic medications within 5 half-lives of these medications"
NCT05369065,Exclusion,"Hepatic decompensation defined as the presence of any of the following: Serum albumin less than 3.5 g/dL International normalization ratio (INR) greater than 1.4 (unless due to therapeutic anticoagulants) Total bilirubin greater than 2 mg/dL with the exception of Gilbert syndrome History of esophageal varices, ascites, or hepatic encephalopathy"
NCT01462266,Inclusion,"has one of the following criteria: diagnosed with diabetes after age 40 years and insulin therapy was initiated at least 3 years following diagnosis if diagnosed with diabetes under age 40 years or insulin started earlier than 3 years after diagnosis, has a fasting C-peptide greater than 0.7 ng/mL"
NCT00770835,Inclusion,"Has one or more cardiovascular comorbidities as follows: stable angina pectoris previous (greater than three months) transient ischemic attack, cerebrovascular accident or carotid atherosclerosis as assessed by bilateral carotid artery ultrasonography peripheral vascular complications documented by a history of claudication or rest pain, ultrasonography or angiography."
NCT03655535,Inclusion,"Established type 2 diabetes as assessed by: Fasting blood glucose (>126 mg/dL/7 mmol/L), or 2 hr oral glucose tolerance test (>200 mg/dL/11.1 mmol/L), or HbA1c is ≥7.0%
within 3 months of enrollment and on a stable dose of metformin and/or sulfonylureas for at least 12 weeks."
NCT02547935,Exclusion,Any of the following CV/Vascular Diseases within 3 month prior to signing the consent at Visit 1: Myocardial infarction cardiac surgery or revascularization (CABG/PTCA) unstable angina unstable HF New York Heart Association (NYHA) Class III-IV transient ischemic attack (TIA) or significant cerebrovascular disease unstable or previously undiagnosed arrhythmia
NCT00487240,Inclusion,"As determined by the investigator, are capable and willing to do the following: perform self monitoring of blood glucose (SMBG), complete patient diaries as required for this protocol, use the insulin injection device(s) according to the instructions provided, are receptive to diabetes education, comply with the required study visits."
NCT01018017,Exclusion,"Renal or liver impairment, defined as: Serum creatinine level of ≥ 1.4 mg/dL for females and ≥ 1.5 mg/dL for males AST and ALT ≥ 2xULN alkaline phosphatase and bilirubin > 1.5xULN (an isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin is <35%)"
NCT01868646,Exclusion,Heart rhythm disorder: II-III atrioventricular block; sick sinus syndrome; long QT interval syndrome; complete left bundle branch block; block of 2/3 bundle branches; WPW syndrome; ventricular arrhythmia of III grade according Laun-Wolf; paroxysmal supraventricular tachycardia; paroxysmal/recurrent ventricular tachycardia; atrial flutter and fibrillation; ventricular flutter and fibrillation; heart pacemaker implant.
NCT03091712,Inclusion,"If female is of childbearing potential, is practicing one of the following methods of birth control (and will continue through the duration of the study): Condoms, sponge, diaphragm, or intrauterine device; Oral or parenteral contraceptives for 3 months prior to screening visit; Vasectomized partner; Total abstinence from sexual intercourse"
NCT02954601,Exclusion,"Any clinically significant ECG abnormality at Screening or cardiovascular disease.
Clinically significant cardiovascular disease will include: History of stroke, transient ischemic attack, or myocardial infarction within 6 months prior to Screening, History of or currently have New York Heart Associate Class II-IV heart failure prior to Screening, or"
NCT04515849,Exclusion,Significant hepatic disease (except for non-alcoholic steatohepatitis or nonalcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results: Aspartate transaminase (AST) ≥ 3 × upper limit of normal (ULN) Alanine transaminase (ALT) ≥ 3 × ULN Total bilirubin ≥ 2 × ULN
NCT03344341,Exclusion,Any of the following cardiovascular diseases within 6 months of the enrollment visit: Myocardial infarction; Cardiac surgery or revascularization (coronary artery bypass graft/percutaneous transluminal coronary angioplasty); Unstable angina; Congestive heart failure New York Heart Association Class III or IV; Transient ischemic attack or significant cerebrovascular disease.
NCT03310749,Exclusion,Subjects who show one of the following results at screening test: Exceeds 1.5 times the upper limit of the normal range of blood AST (SGOT) and ALT (SGPT) The creatinine clearance calculated by Cockcroft-Gault equation is below 80 mL/min. QTc > 450 ms in ECG or clinically significant abnormal rhythm
NCT00879970,Inclusion,"Age ≥ 55 years and evidence of subclinical vascular disease defined as ≥1 of: microalbuminuria or proteinuria history of treated or untreated hypertension with left ventricular hypertrophy by electrocardiogram (ECG) or echocardiogram 50% stenosis on any imaging of coronary, carotid or lower extremity arteries ankle/brachial index <0.9 OR"
NCT04484779,Inclusion,"Using insulin injection regimen of basal/bolus or basal only for 3 months prior to screening, which includes: for bolus insulin (U-100) - a rapid-acting insulin analog (glulisine, lispro, or aspart). for basal insulin - degludec (U-100 or U-200), detemir (U-100), or glargine (U- 100 or U-300)."
NCT02512523,Inclusion,"Patient has adequate renal and hepatic function at screening as defined by the following clinical chemistry results: (male) Serum creatinine <1.5 × upper limit of normal (ULN), (female) Serum creatinine <1.4 × upper limit of normal (ULN), Serum alanine aminotransferase <2.5 × ULN Serum aspartate aminotransferase <2.5 × ULN"
NCT01425359,Inclusion,"CAD documented by one or more of the following: Angiographic evidence of ≥ 50% stenosis of one or more major coronary arteries History of myocardial infarction (MI) documented by positive myocardial muscle creatine kinase (CK-MB) enzymes, troponins, or electrocardiogram (ECG) changes Cardiac imaging study or exercise test diagnostic for CAD"
NCT04865770,Inclusion,"Depending on biopsy/non-biopsy population: For subjects in the non-biopsy population: Serum creatinine-based eGFR greater than or equal to 30 and below or equal to 75 mL/min/1.73
m^2(CKD-EPI). For subjects in the biopsy sub-population: Serum creatinine-based eGFR greater than or equal to 40 and below or equal to 75 mL/min/1.73
m^2(CKD-EPI)."
NCT06151964,Exclusion,Use of any of the following medicinal products: Use of systemic corticosteroids within 28 days prior to screening. Use of compounds known to prolong the QTc interval. Use of any herbal preparations or medicinal products licensed for control of body weight or appetite within 3 months prior to screening.
NCT05803421,Inclusion,"Have increased risk for cardiovascular (CV) events due to: Coronary heart disease Peripheral arterial disease, presumed to be of atherosclerotic origin Cerebrovascular disease, presumed to be of atherosclerotic origin Chronic kidney disease (CKD) Congestive heart failure (CHF) New York Heart Association (NYHA) functional classification II to III"
NCT03745937,Exclusion,Significant hepatic disease (except for nonalcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results at screening: Aspartate transaminase (AST) >= 3 × ULN Alanine transaminase (ALT) >= 3 × ULN Total bilirubin (TBL) >= 2 × ULN
NCT03138356,Inclusion,"For inclusion in the study subjects should fulfill the following criteria: Provision of signed and dated, written informed consent prior to any study specific procedures. Healthy male and/or female subjects aged 18 to 55 years with suitable veins for cannulation or repeated venipuncture. Female subject must either:"
NCT04150107,Inclusion,"Females who are not of childbearing potential are defined as: post-menopausal (defined as at least 12 months with no menses in women ≥45 years of age) or has had a hysterectomy and/or bilateral oophorectomy, or had bilateral tubal ligation or occlusion at least 6 weeks prior to Screening"
NCT03387683,Exclusion,"Any of the following cardiovascular diseases known within 3 months prior to signing the consent at enrolment: Atrial fibrillation, or other unstable or severe arrhythmia affecting heart function Unstable heart failure or any heart failure with NYHA class III and IV Significant valvular disease Significant peripheral artery disease"
NCT05363761,Exclusion,"Hepatic decompensation defined as the presence of any of the following: Serum albumin less than 3.5 g/dL International normalization ratio (INR) greater than 1.4 (unless due to therapeutic anticoagulants) Total bilirubin greater than 2 mg/dL with the exception of Gilbert syndrome History of esophageal varices, ascites, or hepatic encephalopathy"
NCT03550378,Exclusion,Significant hepatic disease (except for non-alcoholic steatohepatitis or nonalcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results: Aspartate transaminase (AST) ≥ 3 × upper limit of normal (ULN) Alanine transaminase (ALT) ≥ 3 × ULN Total bilirubin ≥ 2 × ULN
NCT02561078,Inclusion,"Current TDD >200 but ≤600 units of non U-500R insulin (MDI or CSII) and/or U-500R by MDI with syringe and vial for ≥3 months at entry. If TDD of U-500R and other insulins are combined, then insulin other than U-500R not to exceed 25% of TDD."
NCT02791490,Exclusion,"Has human immunodeficiency virus (HIV) with AIDS related complications, or has not been on a stable anti-retroviral regimen for >6 months, or has progressive disease, or using agents associated with glucose intolerance such as nucleoside reverse transcriptase inhibitors (NRTIs) such as azidothymidine (AZT), didanosine (ddI), and stavudine (d4T)."
NCT01551446,Exclusion,"Recently active cardiovascular disease defined as: Unstable angina pectoris within 12 weeks before Study Day 1; Myocardial infarction, coronary artery bypass graft surgery, or percutaneous transluminal coronary angioplasty/stent within 12 weeks before Study Day 1; Cerebrovascular accident, including transient ischemic attack within 12 weeks before Study Day 1;"
NCT01582451,Exclusion,Lipid-lowering medication: Are using or have used any of the following: niacin preparations as a lipid-lowering medication and/or bile acid sequestrants within 90 days prior to screening or lipid-lowering medication at a dose that has not been stable for at least 90 days prior to screening
NCT01576887,Exclusion,"History of recently active cardiovascular disease defined as: Unstable angina pectoris within 12 weeks before study randomization Myocardial infarction, coronary artery bypass graft surgery, or percutaneous transluminal coronary angioplasty/stent within 12 weeks before study randomization Cerebrovascular accident, including transient ischemic attack within 12 weeks before study randomization"
NCT02079805,Exclusion,"Past or current history of any of the following cardiovascular diseases. Cardiac valve stenosis Angina pectoris requiring medication Congestive cardiac failure requiring medication Arrhythmia requiring medication (e.g., paroxysmal atrial fibrillation, severe bradycardia, torsade de pointes, and ventricular fibrillation) Arteriosclerosis obliterans with intermittent claudication or other symptoms"
NCT04285554,Inclusion,"Type 2 diabetes diagnosis meeting the following criteria: HbA1c > 7.0% and ≤ 9.0% (53 mmol/mol - 75 mmol/mol), AND On at least two anti-diabetic medications; one at the highest tolerated dose with no changes in medication dose in the 12 weeks prior to the first screening visit"
NCT04285554,Exclusion,"Hepatic decompensation defined as the presence of any of the following: Serum albumin less than 3.5 g/dL International normalized ratio (INR) greater than 1.4 (unless due to therapeutic anticoagulants) Total bilirubin greater than 2 mg/dL with the exception of Gilbert syndrome History of esophageal varices, ascites, or hepatic encephalopathy"
NCT04350463,Exclusion,"Subject has previous SARS-CoV-2 infection either suspected or confirmed within 4 weeks prior to screening. Acute symptoms must have resolved and based on Investigator assessment in consultation with the Medical Monitor, there are no sequelae that would place the subject at a higher risk of receiving investigational treatment."
NCT01853826,Exclusion,"radiotherapy within 14 days prior to drug administration, except as follows: Palliative radiation to organs other than chest may be allowed up to 2 weeks prior to drug administration, and Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling."
NCT02044380,Exclusion,"Radiotherapy within 28 days prior to drug administration, except as follows: Palliative radiation to organs other than chest may be allowed up to 2 weeks prior to drug administration, and Single dose palliative treatment for symptomatic metastases outside above allowance to be discussed with sponsor prior to enrolling"
NCT03157089,Exclusion,"Previous or concomitant malignancies at other sites than the lung, except: Effectively treated non-melanoma skin cancers; Effectively treated carcinoma in situ of the cervix; Effectively treated ductal carcinoma in situ; Other effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured."
NCT02082210,Exclusion,"For Part B4 (non-small cell lung cancer) only: The participant has radiologically documented evidence of major blood vessel invasion or encasement by cancer Participants with a history of gross hemoptysis within 2 months prior to study treatment The participant has radiographic evidence of intratumor cavitation, regardless of tumor histology"
NCT01831089,Inclusion,Patients with a histologically/cytologically confirmed diagnosis of advanced and/or unresectable disease of any of the following tumors: Breast cancer Epithelial ovarian cancer or gynecological cancer Head and neck squamous cell carcinoma Non-small cell lung cancer Small cell lung cancer Platinum-refractory germ-cell tumors. Adenocarcinoma or carcinoma of unknown primary site
NCT01945775,Exclusion,Prior malignancy except for any of the following: Prior BRCA-associated cancer as long as there is no current evidence of the cancer Carcinoma in situ or non-melanoma skin cancer A cancer diagnosed and definitively treated ≥ 5 years before randomization with no subsequent evidence of recurrence
NCT01853878,Exclusion,"The patient has received any anti-cancer specific treatment, including radiotherapy, immunotherapy, hormonal therapy, chemotherapy or neo-adjuvant chemotherapy, except for: Administration of adjuvant platinum-based doublet chemotherapy for the treatment of the current NSCLC allowed between surgery and randomization. Treatment of previous malignancies as allowed by the protocol."
NCT01523587,Exclusion,"Female patients of childbearing potential (see Section 4.2.3.3)
who: are nursing or are pregnant or are not using an acceptable method of birth control, or do not plan to continue using this method throughout the study and/or do not agree to submit to pregnancy testing required by this protocol."
NCT01953913,Exclusion,"radiotherapy within 4 weeks prior to drug administration except as follows: palliative radiation to organs other than chest may be allowed up to 2 weeks prior to drug administration, and single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling."
NCT01953913,Exclusion,"childbearing potential (see Section 4.2.3)
who: are nursing or are pregnant or are not using an acceptable method of birth control, or do not plan to continue using this method throughout the trial and/or do not agree to submit to pregnancy testing required by this protocol"
NCT01139775,Inclusion,Phase 2 portion: Have a histological diagnosis of NSCLC other than predominantly squamous cell histology that is classified as Stage IV according to the 7th edition of the AJCC classification Eligible for a first line of palliative treatment with a platinum doublet Have archived or fresh tumor tissue (not cytology)
NCT03310619,Exclusion,Prior treatment with the combination agent from the assigned arm: Anti PD-1 or PD-L1 (Arm A and E) CC-122 (Arm B) CC-220 (Arm C) Prior treatment with ibrutinib is not exclusionary for subjects on any study arm Anti LAG-3 targeted agent (Arm E) CC-99282 (Arm F)
NCT03976375,Inclusion,Has progressive disease (PD) on treatment with one prior anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) monoclonal antibody (mAb) administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies. Retreatment with the same anti-PD-L1/PD-L1 mAb is acceptable in the overall course of treatment
NCT01877083,Inclusion,"Adequate bone marrow function, defined as: Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L (greater than or equal to 1500/mm^3) Hemoglobin (Hb) greater than or equal 8.5 g/dL Platelet count greater than or equal 75 x 10^9/L (greater than or equal 75,000/mm^3)"
NCT02020577,Exclusion,Female patients of childbearing potential who: are nursing or are pregnant or are not using an acceptable method of birth control or do not plan to continue using this method throughout the study and/or do not agree to submit to pregnancy testing required by this protocol.
NCT05205941,Exclusion,"Haematology, biochemistry or urinalysis results that are outside of the laboratory normal reference ranges and are either: considered clinically significant by the Principal Investigator or delegate; OR considered not clinically significant by the Principal Investigator or delegate but are also outside of Sponsor-approved clinically acceptable laboratory ranges"
NCT01500980,Exclusion,"History of: Sickle cell disease, sickle cell trait, or other hemoglobinopathies Splenectomy or functional asplenia Systemic anaphylaxis Gelatin allergy Severe allergic reactions to mosquito bites of study drugs Documented history of chronic or active neurologic disease Psoriasis or porphyria Ocular diseases including retinopathy or visual field defects"
NCT04201431,Inclusion,Answer all questions on the informed consent quiz correctly at first or second attempt Female volunteers are required to use a highly effective form of contraception during the course of the study as malaria challenge could pose a serious risk to both maternal health and the unborn foetus.
NCT02511054,Exclusion,"History of: Sickle cell disease, sickle cell trait, or other hemoglobinopathies Splenectomy or functional asplenia Systemic anaphylaxis Any allergic reactions to study drugs Documented history of chronic or active neurologic disease (including seizures, uncontrolled migraine headaches) Psoriasis or porphyria Ocular diseases including retinopathy or visual field defects"
NCT04241705,Inclusion,For Kebeles: Kebeles in East Hararghe Zone targeted for implementation of elimination activities by the Ethiopian Federal Ministry of Health where there is ongoing PMI-supported malaria surveillance; Kebeles with reported API between 1 and 50; Kebeles in malarious districts with comparable optimization of malaria control interventions.
NCT01434381,Exclusion,"Severe asthma.
This will be defined as: Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past 2 years, or that requires the use of oral or parenteral corticosteroids. Clinically significant reactive airway disease that does not respond to bronchodilators."
NCT00422084,Inclusion,"Presence of acute uncomplicated P. falciparum mono-infection confirmed by: Fever, as defined by axillary/tympanic temperature ≥ 37.5°C or oral/rectal temperature ≥ 38°C, or documented history of fever in the previous 24 hours and, Positive microscopy of P. falciparum with parasite density between 1,000 and 100,000 asexual parasite count/μl of blood."
NCT03780712,Inclusion,Child born from mothers having one of the following criteria before delivery will be included in this study: Spontaneous preterm delivery (<37 weeks of gestation time) Foul smelling / with meconium / colored / bloody amniotic liquid Rupture of membranes > 18 hours Maternal fever at delivery Vaginal infection
NCT07060508,Inclusion,Females of childbearing potential must be willing to use reliable contraception from 21 days prior to study Day 0 through the final study visit as described below. Reliable methods of birth control include 1 of the following: confirmed pharmacologic contraceptives via parenteral delivery or intrauterine or implantable device.
NCT03304704,Inclusion,PARASITE SURVEILLANCE COHORT 6 months to 65 years of age Known resident of Bancoumana or the surrounding villages Willingness to allow stored laboratory specimens to be used for future research Acceptance and signature of the written informed consent and the assent for children aged 12-17 years
NCT02554799,Inclusion,Females must be of non-childbearing potential: Natural (spontaneous) post-menopausal defined (amenorrheic for at least 12 months without an alternative medical cause with a screening follicle stimulating hormone level >25IU/L (for post-menopause). Premenopausal with irreversible surgical sterilization by hysterectomy and/or bilateral oophorectomy or salpingectomy at least 6 months before screening
NCT02773979,Exclusion,Active neoplastic disease*. Subjects with a history of malignancy may be included if treated by surgical excision or if treated by chemotherapy or radiation therapy and has been observed for a period that in the investigator's estimation provides a reasonable assurance of sustained cure (not less than 36 months).
NCT02773979,Exclusion,A screening ECG with abnormalities consistent with underlying heart disease.* Pathologic Q waves and significant ST-T wave changes; left ventricular hypertrophy; any non-sinus rhythm excluding isolated premature atrial or ventricular contractions; right or left bundle branch block; QT/QTc interval > 450 ms; or advanced (secondary or tertiary) A-V heart block.
NCT02773979,Exclusion,"Is using or intends to use a medication that is cross-reactive with CQ** or atovaquone and proguanil, such as cimetidine or metoclopramide, during the study period. Antacids and kaolin can be administered at least 4 hours from intake of chloroquine. Does not apply to infectivity controls"
NCT02083380,Inclusion,"Presence of mono-infection of P. falciparum with: Fever, as defined by axillary temperature ≥ 37.5°C or oral/rectal/tympanic temperature ≥ 38°C, or history of fever in the previous 24 hours (history of fever must be documented) and, Microscopically confirmed parasite infection, in range 1,000 to 100,000 asexual parasites /µL of blood."
NCT00666380,Exclusion,"Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or abnormal baseline laboratory screening tests ALT above normal range Creatinine above normal range Hemoglobin below normal range Platelet count below normal range Total white cell count below normal range"
NCT00298610,Exclusion,"Laboratory evidence or history of significant cardiovascular, liver or renal functional abnormality, which in the opinion of the investigator would place them at increased risk.
Specifically, the following will serve as exclusionary lab values: Creatinine >1.4 x ULN (>2.0 mg/dL) Glucose <LLN (65mg/dL) AST, ALT >3x ULN (120 U/L)"
NCT00487916,Exclusion,"Severe asthma.
This will be defined as: Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past two years or that requires the use of oral or parenteral corticosteroids. Clinically significant reactive airway disease that does not respond to bronchodilators."
NCT05095272,Exclusion,Vital signs taken after 5 minutes of resting in seated or supine position that fall outside the following ranges: Systolic blood pressure <=90 mm Hg or >=140 mm Hg. Diastolic blood pressure <=50 mm Hg or >=90 mm Hg. Heart rate <=40 bpm or >=100 bpm.
NCT00125489,Exclusion,"Signs of severe malaria: One or more of the following: hemoglobin < 5 g/dl parasitemia > 10% prostration * as indicated by inability to drink or breastfeed respiratory distress (deep Kussmaul respirations) bleeding recent seizures*, coma* or mental obtundation* (Blantyre coma score less than 5) persistent vomiting*"
NCT00403260,Inclusion,"Presence of acute uncomplicated P. falciparum mono-infection confirmed by: Fever, as defined by axillary/tympanic temperature ≥37.5°C or oral/rectal temperature ≥38°C, or documented history of fever in the previous 24 hours and, Positive microscopy of P. falciparum with parasite density between 1,000 and 100,000 asexual parasite count/µl of blood"
NCT02458092,Inclusion,• A male or non-lactating female 18 to 50 years of age (inclusive) at the time of screening Free of significant health problems as established by medical history and clinical examination before entering into the study Available to participate for duration of study (approximately seven months)
NCT04327310,Exclusion,"Abnormal vital signs at Screening (supine and standing) and on Day 1 (Parts A and C) or pre-inoculation on Day 8 (Part B) (supine), defined as any of the following: Systolic blood pressure <90 or >140 mmHg. Diastolic blood pressure <40 or >90 mmHg. Pulse rate <40 or >100 bpm."
NCT00414336,Exclusion,"Severe asthma.
This will be defined as: Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past two years or that requires the use of oral or parenteral corticosteroids; Clinically significant reactive airway disease that does not respond to bronchodilators."
NCT06069544,Exclusion,"The following diseases associated with immune dysregulation: Primary immunodeficiencies. History of solid organ or bone marrow transplantation. Asplenia: any condition resulting in the absence of a functional spleen. Currently existing or history of autoimmune disease including and not limited to thyroid autoimmune disease, multiple sclerosis, psoriasis, etc."
NCT05581641,Exclusion,"The following diseases associated with immune dysregulation: Primary immunodeficiencies. History of solid organ or bone marrow transplantation. Asplenia: any condition resulting in the absence of a functional spleen. Currently existing or history of autoimmune disease including and not limited to thyroid autoimmune disease, multiple sclerosis, psoriasis, etc."
NCT01713621,Inclusion,"Presence of mono-infection of P. falciparum confirmed by: Fever, as defined by axillary temperature ≥ 37.5°C or oral/rectal/tympanic temperature ≥ 38°C, or history of fever in the previous 24 hours (history of fever must be documented) and, Microscopically confirmed parasite infection: 1,000 to 75,000 asexual parasite count/µL blood."
NCT00889616,Exclusion,"Severe asthma.
This will be defined as: Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past 2 years, or that requires the use of oral or parenteral corticosteroids Clinically significant reactive airway disease that does not respond to bronchodilators"
NCT00541385,Inclusion,"Presence of acute uncomplicated P. falciparum mono-infection confirmed by: Fever, as defined by axillary temperature ≥37.5°C or oral/tympanic/rectal temperature ≥38°C, or documented history of fever in the previous 24 hours and, Positive microscopy of P. falciparum with parasite density between 1,000 and 200,000 asexual parasite count/µl of blood."
NCT00762957,Exclusion,"Took any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may have interfered with evaluation of the study medication, including: Insulin Oral antidiabetics including sulfonylureas and alpha-glucosidase inhibitors Systemic corticosteroids Warfarin Rifampin St. John's Wort. Thiazolidinediones Peroxisome proliferator-activated receptor agonists Nicotinic Acid Fibrates"
NCT04373265,Exclusion,"Treated with the following prior to the first dose of relacorilant: Any investigational product, systemic anticancer therapy, or radiation therapy within 21 days Antibodies or anticancer vaccines within 60 days Mifepristone or other GR antagonists within 5 half-lives of these medications Adrenostatic medications within 5 half-lives of these medications"
NCT05369065,Exclusion,"Hepatic decompensation defined as the presence of any of the following: Serum albumin less than 3.5 g/dL International normalization ratio (INR) greater than 1.4 (unless due to therapeutic anticoagulants) Total bilirubin greater than 2 mg/dL with the exception of Gilbert syndrome History of esophageal varices, ascites, or hepatic encephalopathy"
NCT03655535,Inclusion,"Established type 2 diabetes as assessed by: Fasting blood glucose (>126 mg/dL/7 mmol/L), or 2 hr oral glucose tolerance test (>200 mg/dL/11.1 mmol/L), or HbA1c is ≥7.0%
within 3 months of enrollment and on a stable dose of metformin and/or sulfonylureas for at least 12 weeks."
NCT02547935,Exclusion,Any of the following CV/Vascular Diseases within 3 month prior to signing the consent at Visit 1: Myocardial infarction cardiac surgery or revascularization (CABG/PTCA) unstable angina unstable HF New York Heart Association (NYHA) Class III-IV transient ischemic attack (TIA) or significant cerebrovascular disease unstable or previously undiagnosed arrhythmia
NCT02974816,Inclusion,"If female is of childbearing potential, is practicing one of the following methods of birth control (and will continue through the duration of the study): Condoms, sponge, diaphragm, or intrauterine device; Oral or parenteral contraceptives for 3 months prior to screening visit; Vasectomized partner; Total abstinence from sexual intercourse"
NCT00487240,Inclusion,"As determined by the investigator, are capable and willing to do the following: perform self monitoring of blood glucose (SMBG), complete patient diaries as required for this protocol, use the insulin injection device(s) according to the instructions provided, are receptive to diabetes education, comply with the required study visits."
NCT03289494,Exclusion,General criteria: Patient under legal protection measure Patient deprived of liberty by a court or an administrative decision Patient currently participating in another study or being in the exclusion period of another study Volunteer that exceed the financial compensation allowed per year for participating in research programs
NCT01868646,Exclusion,Heart rhythm disorder: II-III atrioventricular block; sick sinus syndrome; long QT interval syndrome; complete left bundle branch block; block of 2/3 bundle branches; WPW syndrome; ventricular arrhythmia of III grade according Laun-Wolf; paroxysmal supraventricular tachycardia; paroxysmal/recurrent ventricular tachycardia; atrial flutter and fibrillation; ventricular flutter and fibrillation; heart pacemaker implant.
NCT02954601,Exclusion,"Any clinically significant ECG abnormality at Screening or cardiovascular disease.
Clinically significant cardiovascular disease will include: History of stroke, transient ischemic attack, or myocardial infarction within 6 months prior to Screening, History of or currently have New York Heart Associate Class II-IV heart failure prior to Screening, or"
NCT04515849,Exclusion,Significant hepatic disease (except for non-alcoholic steatohepatitis or nonalcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results: Aspartate transaminase (AST) ≥ 3 × upper limit of normal (ULN) Alanine transaminase (ALT) ≥ 3 × ULN Total bilirubin ≥ 2 × ULN
NCT03310749,Exclusion,Subjects who show one of the following results at screening test: Exceeds 1.5 times the upper limit of the normal range of blood AST (SGOT) and ALT (SGPT) The creatinine clearance calculated by Cockcroft-Gault equation is below 80 mL/min. QTc > 450 ms in ECG or clinically significant abnormal rhythm
NCT00879970,Inclusion,"Age ≥ 55 years and evidence of subclinical vascular disease defined as ≥1 of: microalbuminuria or proteinuria history of treated or untreated hypertension with left ventricular hypertrophy by electrocardiogram (ECG) or echocardiogram 50% stenosis on any imaging of coronary, carotid or lower extremity arteries ankle/brachial index <0.9 OR"
NCT04484779,Inclusion,"Using insulin injection regimen of basal/bolus or basal only for 3 months prior to screening, which includes: for bolus insulin (U-100) - a rapid-acting insulin analog (glulisine, lispro, or aspart). for basal insulin - degludec (U-100 or U-200), detemir (U-100), or glargine (U- 100 or U-300)."
NCT02512523,Inclusion,"Patient has adequate renal and hepatic function at screening as defined by the following clinical chemistry results: (male) Serum creatinine <1.5 × upper limit of normal (ULN), (female) Serum creatinine <1.4 × upper limit of normal (ULN), Serum alanine aminotransferase <2.5 × ULN Serum aspartate aminotransferase <2.5 × ULN"
NCT04865770,Inclusion,"Depending on biopsy/non-biopsy population: For subjects in the non-biopsy population: Serum creatinine-based eGFR greater than or equal to 30 and below or equal to 75 mL/min/1.73
m^2(CKD-EPI). For subjects in the biopsy sub-population: Serum creatinine-based eGFR greater than or equal to 40 and below or equal to 75 mL/min/1.73
m^2(CKD-EPI)."
NCT06151964,Exclusion,Use of any of the following medicinal products: Use of systemic corticosteroids within 28 days prior to screening. Use of compounds known to prolong the QTc interval. Use of any herbal preparations or medicinal products licensed for control of body weight or appetite within 3 months prior to screening.
NCT04047537,Inclusion,"If female, must meet all the following criteria: Not pregnant or breastfeeding If of childbearing potential (including peri-menopausal women who have had a menstrual period within one year) must practice and be willing to continue to practice appropriate birth control during the entire duration of the study"
NCT03745937,Exclusion,Significant hepatic disease (except for nonalcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results at screening: Aspartate transaminase (AST) >= 3 × ULN Alanine transaminase (ALT) >= 3 × ULN Total bilirubin (TBL) >= 2 × ULN
NCT04150107,Inclusion,"Females who are not of childbearing potential are defined as: post-menopausal (defined as at least 12 months with no menses in women ≥45 years of age) or has had a hysterectomy and/or bilateral oophorectomy, or had bilateral tubal ligation or occlusion at least 6 weeks prior to Screening"
NCT03387683,Exclusion,"Any of the following cardiovascular diseases known within 3 months prior to signing the consent at enrolment: Atrial fibrillation, or other unstable or severe arrhythmia affecting heart function Unstable heart failure or any heart failure with NYHA class III and IV Significant valvular disease Significant peripheral artery disease"
NCT05363761,Exclusion,"Hepatic decompensation defined as the presence of any of the following: Serum albumin less than 3.5 g/dL International normalization ratio (INR) greater than 1.4 (unless due to therapeutic anticoagulants) Total bilirubin greater than 2 mg/dL with the exception of Gilbert syndrome History of esophageal varices, ascites, or hepatic encephalopathy"
NCT03550378,Exclusion,Significant hepatic disease (except for non-alcoholic steatohepatitis or nonalcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results: Aspartate transaminase (AST) ≥ 3 × upper limit of normal (ULN) Alanine transaminase (ALT) ≥ 3 × ULN Total bilirubin ≥ 2 × ULN
NCT02561078,Inclusion,"Current TDD >200 but ≤600 units of non U-500R insulin (MDI or CSII) and/or U-500R by MDI with syringe and vial for ≥3 months at entry. If TDD of U-500R and other insulins are combined, then insulin other than U-500R not to exceed 25% of TDD."
NCT02791490,Exclusion,"Has human immunodeficiency virus (HIV) with AIDS related complications, or has not been on a stable anti-retroviral regimen for >6 months, or has progressive disease, or using agents associated with glucose intolerance such as nucleoside reverse transcriptase inhibitors (NRTIs) such as azidothymidine (AZT), didanosine (ddI), and stavudine (d4T)."
NCT01551446,Exclusion,"Recently active cardiovascular disease defined as: Unstable angina pectoris within 12 weeks before Study Day 1; Myocardial infarction, coronary artery bypass graft surgery, or percutaneous transluminal coronary angioplasty/stent within 12 weeks before Study Day 1; Cerebrovascular accident, including transient ischemic attack within 12 weeks before Study Day 1;"
NCT01576887,Exclusion,"History of recently active cardiovascular disease defined as: Unstable angina pectoris within 12 weeks before study randomization Myocardial infarction, coronary artery bypass graft surgery, or percutaneous transluminal coronary angioplasty/stent within 12 weeks before study randomization Cerebrovascular accident, including transient ischemic attack within 12 weeks before study randomization"
NCT02079805,Exclusion,"Past or current history of any of the following cardiovascular diseases. Cardiac valve stenosis Angina pectoris requiring medication Congestive cardiac failure requiring medication Arrhythmia requiring medication (e.g., paroxysmal atrial fibrillation, severe bradycardia, torsade de pointes, and ventricular fibrillation) Arteriosclerosis obliterans with intermittent claudication or other symptoms"
NCT05936151,Inclusion,"Have either no T2D with an HbA1c < 6.5% or have T2D with an HbA1c ≤ 9.5% and treated with diet and exercise only or with stable doses of up to 3 oral antihyperglycemic medications, with or without basal insulin for at least 90 days before screening."
NCT04285554,Inclusion,"Type 2 diabetes diagnosis meeting the following criteria: HbA1c > 7.0% and ≤ 9.0% (53 mmol/mol - 75 mmol/mol), AND On at least two anti-diabetic medications; one at the highest tolerated dose with no changes in medication dose in the 12 weeks prior to the first screening visit"
NCT04285554,Exclusion,"Hepatic decompensation defined as the presence of any of the following: Serum albumin less than 3.5 g/dL International normalized ratio (INR) greater than 1.4 (unless due to therapeutic anticoagulants) Total bilirubin greater than 2 mg/dL with the exception of Gilbert syndrome History of esophageal varices, ascites, or hepatic encephalopathy"
NCT00157196,Inclusion,"Primary therapy should be a minimum of 2 cycles of Platinum-based first-line chemotherapy, given concurrent with thoracic radiation.
The combined modality should consist of either: induction (2 cycles) chemotherapy followed by concurrent chemo-radiation therapy; or concurrent chemo-radiation therapy followed by 2 cycles of consolidation chemotherapy; or concurrent chemoradiation therapy alone"
NCT01853826,Exclusion,"radiotherapy within 14 days prior to drug administration, except as follows: Palliative radiation to organs other than chest may be allowed up to 2 weeks prior to drug administration, and Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling."
NCT02358473,Exclusion,"History of second primary cancer within the past 5 years, with the exception of: Curatively resected non-melanomatous skin cancer; Curatively treated cervical intraepithelial neoplasia or prostate carcinoma with current prostate specific antigen (PSA) < 0.01 ng/mL; or Curatively treated ductal carcinoma in situ of the breast;"
NCT02044380,Exclusion,"Radiotherapy within 28 days prior to drug administration, except as follows: Palliative radiation to organs other than chest may be allowed up to 2 weeks prior to drug administration, and Single dose palliative treatment for symptomatic metastases outside above allowance to be discussed with sponsor prior to enrolling"
NCT03157089,Exclusion,"Previous or concomitant malignancies at other sites than the lung, except: Effectively treated non-melanoma skin cancers; Effectively treated carcinoma in situ of the cervix; Effectively treated ductal carcinoma in situ; Other effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured."
NCT02082210,Exclusion,"For Part B4 (non-small cell lung cancer) only: The participant has radiologically documented evidence of major blood vessel invasion or encasement by cancer Participants with a history of gross hemoptysis within 2 months prior to study treatment The participant has radiographic evidence of intratumor cavitation, regardless of tumor histology"
NCT01831089,Inclusion,Patients with a histologically/cytologically confirmed diagnosis of advanced and/or unresectable disease of any of the following tumors: Breast cancer Epithelial ovarian cancer or gynecological cancer Head and neck squamous cell carcinoma Non-small cell lung cancer Small cell lung cancer Platinum-refractory germ-cell tumors. Adenocarcinoma or carcinoma of unknown primary site
NCT01945775,Exclusion,Prior malignancy except for any of the following: Prior BRCA-associated cancer as long as there is no current evidence of the cancer Carcinoma in situ or non-melanoma skin cancer A cancer diagnosed and definitively treated ≥ 5 years before randomization with no subsequent evidence of recurrence
NCT01853878,Exclusion,"The patient has received any anti-cancer specific treatment, including radiotherapy, immunotherapy, hormonal therapy, chemotherapy or neo-adjuvant chemotherapy, except for: Administration of adjuvant platinum-based doublet chemotherapy for the treatment of the current NSCLC allowed between surgery and randomization. Treatment of previous malignancies as allowed by the protocol."
NCT01523587,Exclusion,"Female patients of childbearing potential (see Section 4.2.3.3)
who: are nursing or are pregnant or are not using an acceptable method of birth control, or do not plan to continue using this method throughout the study and/or do not agree to submit to pregnancy testing required by this protocol."
NCT01953913,Exclusion,"radiotherapy within 4 weeks prior to drug administration except as follows: palliative radiation to organs other than chest may be allowed up to 2 weeks prior to drug administration, and single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling."
NCT01953913,Exclusion,"childbearing potential (see Section 4.2.3)
who: are nursing or are pregnant or are not using an acceptable method of birth control, or do not plan to continue using this method throughout the trial and/or do not agree to submit to pregnancy testing required by this protocol"
NCT01139775,Inclusion,Phase 2 portion: Have a histological diagnosis of NSCLC other than predominantly squamous cell histology that is classified as Stage IV according to the 7th edition of the AJCC classification Eligible for a first line of palliative treatment with a platinum doublet Have archived or fresh tumor tissue (not cytology)
NCT03976375,Inclusion,Has progressive disease (PD) on treatment with one prior anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) monoclonal antibody (mAb) administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies. Retreatment with the same anti-PD-L1/PD-L1 mAb is acceptable in the overall course of treatment
NCT01877083,Inclusion,"Adequate bone marrow function, defined as: Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L (greater than or equal to 1500/mm^3) Hemoglobin (Hb) greater than or equal 8.5 g/dL Platelet count greater than or equal 75 x 10^9/L (greater than or equal 75,000/mm^3)"
NCT02020577,Exclusion,Female patients of childbearing potential who: are nursing or are pregnant or are not using an acceptable method of birth control or do not plan to continue using this method throughout the study and/or do not agree to submit to pregnancy testing required by this protocol.
NCT05205941,Exclusion,"Haematology, biochemistry or urinalysis results that are outside of the laboratory normal reference ranges and are either: considered clinically significant by the Principal Investigator or delegate; OR considered not clinically significant by the Principal Investigator or delegate but are also outside of Sponsor-approved clinically acceptable laboratory ranges"
NCT04201431,Inclusion,Answer all questions on the informed consent quiz correctly at first or second attempt Female volunteers are required to use a highly effective form of contraception during the course of the study as malaria challenge could pose a serious risk to both maternal health and the unborn foetus.
NCT02511054,Exclusion,"History of: Sickle cell disease, sickle cell trait, or other hemoglobinopathies Splenectomy or functional asplenia Systemic anaphylaxis Any allergic reactions to study drugs Documented history of chronic or active neurologic disease (including seizures, uncontrolled migraine headaches) Psoriasis or porphyria Ocular diseases including retinopathy or visual field defects"
NCT01434381,Exclusion,"Severe asthma.
This will be defined as: Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past 2 years, or that requires the use of oral or parenteral corticosteroids. Clinically significant reactive airway disease that does not respond to bronchodilators."
NCT03780712,Inclusion,Child born from mothers having one of the following criteria before delivery will be included in this study: Spontaneous preterm delivery (<37 weeks of gestation time) Foul smelling / with meconium / colored / bloody amniotic liquid Rupture of membranes > 18 hours Maternal fever at delivery Vaginal infection
NCT07060508,Inclusion,Females of childbearing potential must be willing to use reliable contraception from 21 days prior to study Day 0 through the final study visit as described below. Reliable methods of birth control include 1 of the following: confirmed pharmacologic contraceptives via parenteral delivery or intrauterine or implantable device.
NCT02554799,Inclusion,Females must be of non-childbearing potential: Natural (spontaneous) post-menopausal defined (amenorrheic for at least 12 months without an alternative medical cause with a screening follicle stimulating hormone level >25IU/L (for post-menopause). Premenopausal with irreversible surgical sterilization by hysterectomy and/or bilateral oophorectomy or salpingectomy at least 6 months before screening
NCT02083380,Inclusion,"Presence of mono-infection of P. falciparum with: Fever, as defined by axillary temperature ≥ 37.5°C or oral/rectal/tympanic temperature ≥ 38°C, or history of fever in the previous 24 hours (history of fever must be documented) and, Microscopically confirmed parasite infection, in range 1,000 to 100,000 asexual parasites /µL of blood."
NCT00666380,Exclusion,"Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or abnormal baseline laboratory screening tests ALT above normal range Creatinine above normal range Hemoglobin below normal range Platelet count below normal range Total white cell count below normal range"
NCT00298610,Exclusion,"Laboratory evidence or history of significant cardiovascular, liver or renal functional abnormality, which in the opinion of the investigator would place them at increased risk.
Specifically, the following will serve as exclusionary lab values: Creatinine >1.4 x ULN (>2.0 mg/dL) Glucose <LLN (65mg/dL) AST, ALT >3x ULN (120 U/L)"
NCT05095272,Exclusion,Vital signs taken after 5 minutes of resting in seated or supine position that fall outside the following ranges: Systolic blood pressure <=90 mm Hg or >=140 mm Hg. Diastolic blood pressure <=50 mm Hg or >=90 mm Hg. Heart rate <=40 bpm or >=100 bpm.
NCT04327310,Exclusion,"Abnormal vital signs at Screening (supine and standing) and on Day 1 (Parts A and C) or pre-inoculation on Day 8 (Part B) (supine), defined as any of the following: Systolic blood pressure <90 or >140 mmHg. Diastolic blood pressure <40 or >90 mmHg. Pulse rate <40 or >100 bpm."
NCT06069544,Exclusion,"The following diseases associated with immune dysregulation: Primary immunodeficiencies. History of solid organ or bone marrow transplantation. Asplenia: any condition resulting in the absence of a functional spleen. Currently existing or history of autoimmune disease including and not limited to thyroid autoimmune disease, multiple sclerosis, psoriasis, etc."
NCT05581641,Exclusion,"The following diseases associated with immune dysregulation: Primary immunodeficiencies. History of solid organ or bone marrow transplantation. Asplenia: any condition resulting in the absence of a functional spleen. Currently existing or history of autoimmune disease including and not limited to thyroid autoimmune disease, multiple sclerosis, psoriasis, etc."
NCT01713621,Inclusion,"Presence of mono-infection of P. falciparum confirmed by: Fever, as defined by axillary temperature ≥ 37.5°C or oral/rectal/tympanic temperature ≥ 38°C, or history of fever in the previous 24 hours (history of fever must be documented) and, Microscopically confirmed parasite infection: 1,000 to 75,000 asexual parasite count/µL blood."
NCT00541385,Inclusion,"Presence of acute uncomplicated P. falciparum mono-infection confirmed by: Fever, as defined by axillary temperature ≥37.5°C or oral/tympanic/rectal temperature ≥38°C, or documented history of fever in the previous 24 hours and, Positive microscopy of P. falciparum with parasite density between 1,000 and 200,000 asexual parasite count/µl of blood."
NCT00762957,Exclusion,"Took any disallowed medication, prescription medication, herbal treatment or over-the counter medication that may have interfered with evaluation of the study medication, including: Insulin Oral antidiabetics including sulfonylureas and alpha-glucosidase inhibitors Systemic corticosteroids Warfarin Rifampin St. John's Wort. Thiazolidinediones Peroxisome proliferator-activated receptor agonists Nicotinic Acid Fibrates"
NCT06473662,Exclusion,"History of diabetic ketoacidosis requiring hospitalization within 6 months prior to enrolment, case of proliferative retinopathy or advanced neuropathy Subject having any of the following laboratory results at screening Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73
m2 Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) >3 times of upper limit normal"
NCT01462266,Inclusion,"has one of the following criteria: diagnosed with diabetes after age 40 years and insulin therapy was initiated at least 3 years following diagnosis if diagnosed with diabetes under age 40 years or insulin started earlier than 3 years after diagnosis, has a fasting C-peptide greater than 0.7 ng/mL"
NCT03655535,Inclusion,"Established type 2 diabetes as assessed by: Fasting blood glucose (>126 mg/dL/7 mmol/L), or 2 hr oral glucose tolerance test (>200 mg/dL/11.1 mmol/L), or HbA1c is ≥7.0%
within 3 months of enrollment and on a stable dose of metformin and/or sulfonylureas for at least 12 weeks."
NCT02547935,Exclusion,Any of the following CV/Vascular Diseases within 3 month prior to signing the consent at Visit 1: Myocardial infarction cardiac surgery or revascularization (CABG/PTCA) unstable angina unstable HF New York Heart Association (NYHA) Class III-IV transient ischemic attack (TIA) or significant cerebrovascular disease unstable or previously undiagnosed arrhythmia
NCT02689362,Exclusion,"Concomitant use of drugs or foods that interfere with the CYP3A4 pathway of liver metabolism including, but not limited to: Inhibitors: antibacterial agents (erythromycin), antifungals (itraconazole, ketoconazole), antivirals (ritonavir, saquinavir, amprenavir, indinavir, nelfinavir), H2 receptor antagonists (cimetidine) and grapefruit juice; Inducers: dexamethasone, rifampin and anticonvulsants (phenytoin, phenobarbital, carbamazepine)"
NCT00487240,Inclusion,"As determined by the investigator, are capable and willing to do the following: perform self monitoring of blood glucose (SMBG), complete patient diaries as required for this protocol, use the insulin injection device(s) according to the instructions provided, are receptive to diabetes education, comply with the required study visits."
NCT03289494,Exclusion,General criteria: Patient under legal protection measure Patient deprived of liberty by a court or an administrative decision Patient currently participating in another study or being in the exclusion period of another study Volunteer that exceed the financial compensation allowed per year for participating in research programs
NCT01868646,Exclusion,Heart rhythm disorder: II-III atrioventricular block; sick sinus syndrome; long QT interval syndrome; complete left bundle branch block; block of 2/3 bundle branches; WPW syndrome; ventricular arrhythmia of III grade according Laun-Wolf; paroxysmal supraventricular tachycardia; paroxysmal/recurrent ventricular tachycardia; atrial flutter and fibrillation; ventricular flutter and fibrillation; heart pacemaker implant.
NCT05834868,Inclusion,"Treated with stable insulin regimen as follow for at least 3 months with or without oral antidiabetic drug: Basal insulin (neutral protamine Hagedorn [NPH] insulin, insulin glargine, insulin degludec, insulin detemir) in combination with at least 1 prandial injection of bolus insulin. Premixed insulin at least twice daily."
NCT02954601,Exclusion,"Any clinically significant ECG abnormality at Screening or cardiovascular disease.
Clinically significant cardiovascular disease will include: History of stroke, transient ischemic attack, or myocardial infarction within 6 months prior to Screening, History of or currently have New York Heart Associate Class II-IV heart failure prior to Screening, or"
NCT04515849,Exclusion,Significant hepatic disease (except for non-alcoholic steatohepatitis or nonalcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results: Aspartate transaminase (AST) ≥ 3 × upper limit of normal (ULN) Alanine transaminase (ALT) ≥ 3 × ULN Total bilirubin ≥ 2 × ULN
NCT03344341,Exclusion,Any of the following cardiovascular diseases within 6 months of the enrollment visit: Myocardial infarction; Cardiac surgery or revascularization (coronary artery bypass graft/percutaneous transluminal coronary angioplasty); Unstable angina; Congestive heart failure New York Heart Association Class III or IV; Transient ischemic attack or significant cerebrovascular disease.
NCT03310749,Exclusion,Subjects who show one of the following results at screening test: Exceeds 1.5 times the upper limit of the normal range of blood AST (SGOT) and ALT (SGPT) The creatinine clearance calculated by Cockcroft-Gault equation is below 80 mL/min. QTc > 450 ms in ECG or clinically significant abnormal rhythm
NCT00879970,Inclusion,"Age ≥ 55 years and evidence of subclinical vascular disease defined as ≥1 of: microalbuminuria or proteinuria history of treated or untreated hypertension with left ventricular hypertrophy by electrocardiogram (ECG) or echocardiogram 50% stenosis on any imaging of coronary, carotid or lower extremity arteries ankle/brachial index <0.9 OR"
NCT02512523,Inclusion,"Patient has adequate renal and hepatic function at screening as defined by the following clinical chemistry results: (male) Serum creatinine <1.5 × upper limit of normal (ULN), (female) Serum creatinine <1.4 × upper limit of normal (ULN), Serum alanine aminotransferase <2.5 × ULN Serum aspartate aminotransferase <2.5 × ULN"
NCT06151964,Exclusion,Use of any of the following medicinal products: Use of systemic corticosteroids within 28 days prior to screening. Use of compounds known to prolong the QTc interval. Use of any herbal preparations or medicinal products licensed for control of body weight or appetite within 3 months prior to screening.
NCT05803421,Inclusion,"Have increased risk for cardiovascular (CV) events due to: Coronary heart disease Peripheral arterial disease, presumed to be of atherosclerotic origin Cerebrovascular disease, presumed to be of atherosclerotic origin Chronic kidney disease (CKD) Congestive heart failure (CHF) New York Heart Association (NYHA) functional classification II to III"
NCT00320021,Inclusion,Patients with diagnosis of diabetic nephropathy as defined by Serum Creatinine <=2.0 mg/dL at weeks -2 and -1 (PYR-205) Serum Creatinine >2.0 mg/dL but <=3.5 mg/dL at weeks -2 and -1 (PYR-207) Urinary albumin excretion >=300 mg/24 hours at week -2 No other known or suspected etiology for nephropathy
NCT03745937,Exclusion,Significant hepatic disease (except for nonalcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results at screening: Aspartate transaminase (AST) >= 3 × ULN Alanine transaminase (ALT) >= 3 × ULN Total bilirubin (TBL) >= 2 × ULN
NCT03138356,Inclusion,"For inclusion in the study subjects should fulfill the following criteria: Provision of signed and dated, written informed consent prior to any study specific procedures. Healthy male and/or female subjects aged 18 to 55 years with suitable veins for cannulation or repeated venipuncture. Female subject must either:"
NCT04150107,Inclusion,"Females who are not of childbearing potential are defined as: post-menopausal (defined as at least 12 months with no menses in women ≥45 years of age) or has had a hysterectomy and/or bilateral oophorectomy, or had bilateral tubal ligation or occlusion at least 6 weeks prior to Screening"
NCT03550378,Exclusion,Significant hepatic disease (except for non-alcoholic steatohepatitis or nonalcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results: Aspartate transaminase (AST) ≥ 3 × upper limit of normal (ULN) Alanine transaminase (ALT) ≥ 3 × ULN Total bilirubin ≥ 2 × ULN
NCT02791490,Exclusion,"Has human immunodeficiency virus (HIV) with AIDS related complications, or has not been on a stable anti-retroviral regimen for >6 months, or has progressive disease, or using agents associated with glucose intolerance such as nucleoside reverse transcriptase inhibitors (NRTIs) such as azidothymidine (AZT), didanosine (ddI), and stavudine (d4T)."
NCT01551446,Exclusion,"Recently active cardiovascular disease defined as: Unstable angina pectoris within 12 weeks before Study Day 1; Myocardial infarction, coronary artery bypass graft surgery, or percutaneous transluminal coronary angioplasty/stent within 12 weeks before Study Day 1; Cerebrovascular accident, including transient ischemic attack within 12 weeks before Study Day 1;"
NCT01582451,Exclusion,Lipid-lowering medication: Are using or have used any of the following: niacin preparations as a lipid-lowering medication and/or bile acid sequestrants within 90 days prior to screening or lipid-lowering medication at a dose that has not been stable for at least 90 days prior to screening
NCT01576887,Exclusion,"History of recently active cardiovascular disease defined as: Unstable angina pectoris within 12 weeks before study randomization Myocardial infarction, coronary artery bypass graft surgery, or percutaneous transluminal coronary angioplasty/stent within 12 weeks before study randomization Cerebrovascular accident, including transient ischemic attack within 12 weeks before study randomization"
NCT02079805,Exclusion,"Past or current history of any of the following cardiovascular diseases. Cardiac valve stenosis Angina pectoris requiring medication Congestive cardiac failure requiring medication Arrhythmia requiring medication (e.g., paroxysmal atrial fibrillation, severe bradycardia, torsade de pointes, and ventricular fibrillation) Arteriosclerosis obliterans with intermittent claudication or other symptoms"
NCT05936151,Inclusion,"Have either no T2D with an HbA1c < 6.5% or have T2D with an HbA1c ≤ 9.5% and treated with diet and exercise only or with stable doses of up to 3 oral antihyperglycemic medications, with or without basal insulin for at least 90 days before screening."
NCT04350463,Exclusion,"Subject has previous SARS-CoV-2 infection either suspected or confirmed within 4 weeks prior to screening. Acute symptoms must have resolved and based on Investigator assessment in consultation with the Medical Monitor, there are no sequelae that would place the subject at a higher risk of receiving investigational treatment."
NCT00157196,Inclusion,"Primary therapy should be a minimum of 2 cycles of Platinum-based first-line chemotherapy, given concurrent with thoracic radiation.
The combined modality should consist of either: induction (2 cycles) chemotherapy followed by concurrent chemo-radiation therapy; or concurrent chemo-radiation therapy followed by 2 cycles of consolidation chemotherapy; or concurrent chemoradiation therapy alone"
NCT01853826,Exclusion,"radiotherapy within 14 days prior to drug administration, except as follows: Palliative radiation to organs other than chest may be allowed up to 2 weeks prior to drug administration, and Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling."
NCT02358473,Exclusion,"History of second primary cancer within the past 5 years, with the exception of: Curatively resected non-melanomatous skin cancer; Curatively treated cervical intraepithelial neoplasia or prostate carcinoma with current prostate specific antigen (PSA) < 0.01 ng/mL; or Curatively treated ductal carcinoma in situ of the breast;"
NCT02044380,Exclusion,"Radiotherapy within 28 days prior to drug administration, except as follows: Palliative radiation to organs other than chest may be allowed up to 2 weeks prior to drug administration, and Single dose palliative treatment for symptomatic metastases outside above allowance to be discussed with sponsor prior to enrolling"
NCT03157089,Exclusion,"Previous or concomitant malignancies at other sites than the lung, except: Effectively treated non-melanoma skin cancers; Effectively treated carcinoma in situ of the cervix; Effectively treated ductal carcinoma in situ; Other effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured."
NCT02082210,Exclusion,"For Part B4 (non-small cell lung cancer) only: The participant has radiologically documented evidence of major blood vessel invasion or encasement by cancer Participants with a history of gross hemoptysis within 2 months prior to study treatment The participant has radiographic evidence of intratumor cavitation, regardless of tumor histology"
NCT01970540,Inclusion,"Patients with a histologically/cytologically confirmed diagnosis of advanced disease of any of the following tumors: Breast cancer Soft-tissue sarcoma Primary bone sarcomas. Gynecologic tumors (endometrial adenocarcinomas, epithelial ovarian cancer...) Hepatocellular carcinoma Gastroenteropancreatic neuroendocrine tumors Small cell lung cancer (SCLC) Gastric cancer Bladder cancer Adenocarcinoma of unknown primary site"
NCT04902885,Inclusion,"Histologically or cytologically confirmed extensive stage small cell lung cancer (ES-SCLC): Patients scheduled to receive carboplatin plus etoposide regimen: no prior systemic therapy (eg, chemotherapy or combined with immunotherapy); Patients scheduled to receive topotecan regimen: previously received 1/2 lines of chemotherapy or combined immunotherapy but not topotecan."
NCT01523587,Exclusion,"Female patients of childbearing potential (see Section 4.2.3.3)
who: are nursing or are pregnant or are not using an acceptable method of birth control, or do not plan to continue using this method throughout the study and/or do not agree to submit to pregnancy testing required by this protocol."
NCT01953913,Exclusion,"radiotherapy within 4 weeks prior to drug administration except as follows: palliative radiation to organs other than chest may be allowed up to 2 weeks prior to drug administration, and single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling."
NCT01953913,Exclusion,"childbearing potential (see Section 4.2.3)
who: are nursing or are pregnant or are not using an acceptable method of birth control, or do not plan to continue using this method throughout the trial and/or do not agree to submit to pregnancy testing required by this protocol"
NCT01139775,Inclusion,Phase 2 portion: Have a histological diagnosis of NSCLC other than predominantly squamous cell histology that is classified as Stage IV according to the 7th edition of the AJCC classification Eligible for a first line of palliative treatment with a platinum doublet Have archived or fresh tumor tissue (not cytology)
NCT03976375,Inclusion,Has progressive disease (PD) on treatment with one prior anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) monoclonal antibody (mAb) administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies. Retreatment with the same anti-PD-L1/PD-L1 mAb is acceptable in the overall course of treatment
NCT01877083,Inclusion,"Adequate bone marrow function, defined as: Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L (greater than or equal to 1500/mm^3) Hemoglobin (Hb) greater than or equal 8.5 g/dL Platelet count greater than or equal 75 x 10^9/L (greater than or equal 75,000/mm^3)"
NCT02020577,Exclusion,Female patients of childbearing potential who: are nursing or are pregnant or are not using an acceptable method of birth control or do not plan to continue using this method throughout the study and/or do not agree to submit to pregnancy testing required by this protocol.
NCT05205941,Exclusion,"Haematology, biochemistry or urinalysis results that are outside of the laboratory normal reference ranges and are either: considered clinically significant by the Principal Investigator or delegate; OR considered not clinically significant by the Principal Investigator or delegate but are also outside of Sponsor-approved clinically acceptable laboratory ranges"
NCT04201431,Inclusion,Answer all questions on the informed consent quiz correctly at first or second attempt Female volunteers are required to use a highly effective form of contraception during the course of the study as malaria challenge could pose a serious risk to both maternal health and the unborn foetus.
NCT02511054,Exclusion,"History of: Sickle cell disease, sickle cell trait, or other hemoglobinopathies Splenectomy or functional asplenia Systemic anaphylaxis Any allergic reactions to study drugs Documented history of chronic or active neurologic disease (including seizures, uncontrolled migraine headaches) Psoriasis or porphyria Ocular diseases including retinopathy or visual field defects"
NCT07060508,Inclusion,Females of childbearing potential must be willing to use reliable contraception from 21 days prior to study Day 0 through the final study visit as described below. Reliable methods of birth control include 1 of the following: confirmed pharmacologic contraceptives via parenteral delivery or intrauterine or implantable device.
NCT02554799,Inclusion,Females must be of non-childbearing potential: Natural (spontaneous) post-menopausal defined (amenorrheic for at least 12 months without an alternative medical cause with a screening follicle stimulating hormone level >25IU/L (for post-menopause). Premenopausal with irreversible surgical sterilization by hysterectomy and/or bilateral oophorectomy or salpingectomy at least 6 months before screening
NCT02773979,Exclusion,Active neoplastic disease*. Subjects with a history of malignancy may be included if treated by surgical excision or if treated by chemotherapy or radiation therapy and has been observed for a period that in the investigator's estimation provides a reasonable assurance of sustained cure (not less than 36 months).
NCT02773979,Exclusion,A screening ECG with abnormalities consistent with underlying heart disease.* Pathologic Q waves and significant ST-T wave changes; left ventricular hypertrophy; any non-sinus rhythm excluding isolated premature atrial or ventricular contractions; right or left bundle branch block; QT/QTc interval > 450 ms; or advanced (secondary or tertiary) A-V heart block.
NCT02773979,Exclusion,"Is using or intends to use a medication that is cross-reactive with CQ** or atovaquone and proguanil, such as cimetidine or metoclopramide, during the study period. Antacids and kaolin can be administered at least 4 hours from intake of chloroquine. Does not apply to infectivity controls"
NCT02083380,Inclusion,"Presence of mono-infection of P. falciparum with: Fever, as defined by axillary temperature ≥ 37.5°C or oral/rectal/tympanic temperature ≥ 38°C, or history of fever in the previous 24 hours (history of fever must be documented) and, Microscopically confirmed parasite infection, in range 1,000 to 100,000 asexual parasites /µL of blood."
NCT00666380,Exclusion,"Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or abnormal baseline laboratory screening tests ALT above normal range Creatinine above normal range Hemoglobin below normal range Platelet count below normal range Total white cell count below normal range"
NCT05095272,Exclusion,Vital signs taken after 5 minutes of resting in seated or supine position that fall outside the following ranges: Systolic blood pressure <=90 mm Hg or >=140 mm Hg. Diastolic blood pressure <=50 mm Hg or >=90 mm Hg. Heart rate <=40 bpm or >=100 bpm.
NCT02458092,Inclusion,• A male or non-lactating female 18 to 50 years of age (inclusive) at the time of screening Free of significant health problems as established by medical history and clinical examination before entering into the study Available to participate for duration of study (approximately seven months)
NCT04327310,Exclusion,"Abnormal vital signs at Screening (supine and standing) and on Day 1 (Parts A and C) or pre-inoculation on Day 8 (Part B) (supine), defined as any of the following: Systolic blood pressure <90 or >140 mmHg. Diastolic blood pressure <40 or >90 mmHg. Pulse rate <40 or >100 bpm."
NCT06069544,Exclusion,"The following diseases associated with immune dysregulation: Primary immunodeficiencies. History of solid organ or bone marrow transplantation. Asplenia: any condition resulting in the absence of a functional spleen. Currently existing or history of autoimmune disease including and not limited to thyroid autoimmune disease, multiple sclerosis, psoriasis, etc."
NCT05581641,Exclusion,"The following diseases associated with immune dysregulation: Primary immunodeficiencies. History of solid organ or bone marrow transplantation. Asplenia: any condition resulting in the absence of a functional spleen. Currently existing or history of autoimmune disease including and not limited to thyroid autoimmune disease, multiple sclerosis, psoriasis, etc."
NCT04373265,Exclusion,"Treated with the following prior to the first dose of relacorilant: Any investigational product, systemic anticancer therapy, or radiation therapy within 21 days Antibodies or anticancer vaccines within 60 days Mifepristone or other GR antagonists within 5 half-lives of these medications Adrenostatic medications within 5 half-lives of these medications"
NCT03655535,Inclusion,"Established type 2 diabetes as assessed by: Fasting blood glucose (>126 mg/dL/7 mmol/L), or 2 hr oral glucose tolerance test (>200 mg/dL/11.1 mmol/L), or HbA1c is ≥7.0%
within 3 months of enrollment and on a stable dose of metformin and/or sulfonylureas for at least 12 weeks."
NCT01018017,Exclusion,"Renal or liver impairment, defined as: Serum creatinine level of ≥ 1.4 mg/dL for females and ≥ 1.5 mg/dL for males AST and ALT ≥ 2xULN alkaline phosphatase and bilirubin > 1.5xULN (an isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin is <35%)"
NCT01868646,Exclusion,Heart rhythm disorder: II-III atrioventricular block; sick sinus syndrome; long QT interval syndrome; complete left bundle branch block; block of 2/3 bundle branches; WPW syndrome; ventricular arrhythmia of III grade according Laun-Wolf; paroxysmal supraventricular tachycardia; paroxysmal/recurrent ventricular tachycardia; atrial flutter and fibrillation; ventricular flutter and fibrillation; heart pacemaker implant.
NCT03091712,Inclusion,"If female is of childbearing potential, is practicing one of the following methods of birth control (and will continue through the duration of the study): Condoms, sponge, diaphragm, or intrauterine device; Oral or parenteral contraceptives for 3 months prior to screening visit; Vasectomized partner; Total abstinence from sexual intercourse"
NCT05834868,Inclusion,"Treated with stable insulin regimen as follow for at least 3 months with or without oral antidiabetic drug: Basal insulin (neutral protamine Hagedorn [NPH] insulin, insulin glargine, insulin degludec, insulin detemir) in combination with at least 1 prandial injection of bolus insulin. Premixed insulin at least twice daily."
NCT02954601,Exclusion,"Any clinically significant ECG abnormality at Screening or cardiovascular disease.
Clinically significant cardiovascular disease will include: History of stroke, transient ischemic attack, or myocardial infarction within 6 months prior to Screening, History of or currently have New York Heart Associate Class II-IV heart failure prior to Screening, or"
NCT06152042,Inclusion,Diagnosed with stage 3 T1D within the following timeframes: Part 1 Cohort 1: Participants diagnosed within 3 years prior to screening. Part 1 Cohort 2: Participants diagnosed between 3 to 15 years prior to screening Part 2 : Participants diagnosed within 15 years prior to screening.
NCT04515849,Exclusion,Significant hepatic disease (except for non-alcoholic steatohepatitis or nonalcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results: Aspartate transaminase (AST) ≥ 3 × upper limit of normal (ULN) Alanine transaminase (ALT) ≥ 3 × ULN Total bilirubin ≥ 2 × ULN
NCT03310749,Exclusion,Subjects who show one of the following results at screening test: Exceeds 1.5 times the upper limit of the normal range of blood AST (SGOT) and ALT (SGPT) The creatinine clearance calculated by Cockcroft-Gault equation is below 80 mL/min. QTc > 450 ms in ECG or clinically significant abnormal rhythm
NCT04484779,Inclusion,"Using insulin injection regimen of basal/bolus or basal only for 3 months prior to screening, which includes: for bolus insulin (U-100) - a rapid-acting insulin analog (glulisine, lispro, or aspart). for basal insulin - degludec (U-100 or U-200), detemir (U-100), or glargine (U- 100 or U-300)."
NCT02512523,Inclusion,"Patient has adequate renal and hepatic function at screening as defined by the following clinical chemistry results: (male) Serum creatinine <1.5 × upper limit of normal (ULN), (female) Serum creatinine <1.4 × upper limit of normal (ULN), Serum alanine aminotransferase <2.5 × ULN Serum aspartate aminotransferase <2.5 × ULN"
NCT04865770,Inclusion,"Depending on biopsy/non-biopsy population: For subjects in the non-biopsy population: Serum creatinine-based eGFR greater than or equal to 30 and below or equal to 75 mL/min/1.73
m^2(CKD-EPI). For subjects in the biopsy sub-population: Serum creatinine-based eGFR greater than or equal to 40 and below or equal to 75 mL/min/1.73
m^2(CKD-EPI)."
NCT06151964,Exclusion,Use of any of the following medicinal products: Use of systemic corticosteroids within 28 days prior to screening. Use of compounds known to prolong the QTc interval. Use of any herbal preparations or medicinal products licensed for control of body weight or appetite within 3 months prior to screening.
NCT03745937,Exclusion,Significant hepatic disease (except for nonalcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results at screening: Aspartate transaminase (AST) >= 3 × ULN Alanine transaminase (ALT) >= 3 × ULN Total bilirubin (TBL) >= 2 × ULN
NCT03138356,Inclusion,"For inclusion in the study subjects should fulfill the following criteria: Provision of signed and dated, written informed consent prior to any study specific procedures. Healthy male and/or female subjects aged 18 to 55 years with suitable veins for cannulation or repeated venipuncture. Female subject must either:"
NCT04150107,Inclusion,"Females who are not of childbearing potential are defined as: post-menopausal (defined as at least 12 months with no menses in women ≥45 years of age) or has had a hysterectomy and/or bilateral oophorectomy, or had bilateral tubal ligation or occlusion at least 6 weeks prior to Screening"
NCT03550378,Exclusion,Significant hepatic disease (except for non-alcoholic steatohepatitis or nonalcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results: Aspartate transaminase (AST) ≥ 3 × upper limit of normal (ULN) Alanine transaminase (ALT) ≥ 3 × ULN Total bilirubin ≥ 2 × ULN
NCT02561078,Inclusion,"Current TDD >200 but ≤600 units of non U-500R insulin (MDI or CSII) and/or U-500R by MDI with syringe and vial for ≥3 months at entry. If TDD of U-500R and other insulins are combined, then insulin other than U-500R not to exceed 25% of TDD."
NCT02791490,Exclusion,"Has human immunodeficiency virus (HIV) with AIDS related complications, or has not been on a stable anti-retroviral regimen for >6 months, or has progressive disease, or using agents associated with glucose intolerance such as nucleoside reverse transcriptase inhibitors (NRTIs) such as azidothymidine (AZT), didanosine (ddI), and stavudine (d4T)."
NCT01582451,Exclusion,Lipid-lowering medication: Are using or have used any of the following: niacin preparations as a lipid-lowering medication and/or bile acid sequestrants within 90 days prior to screening or lipid-lowering medication at a dose that has not been stable for at least 90 days prior to screening
NCT01576887,Exclusion,"History of recently active cardiovascular disease defined as: Unstable angina pectoris within 12 weeks before study randomization Myocardial infarction, coronary artery bypass graft surgery, or percutaneous transluminal coronary angioplasty/stent within 12 weeks before study randomization Cerebrovascular accident, including transient ischemic attack within 12 weeks before study randomization"
NCT02044380,Exclusion,"Radiotherapy within 28 days prior to drug administration, except as follows: Palliative radiation to organs other than chest may be allowed up to 2 weeks prior to drug administration, and Single dose palliative treatment for symptomatic metastases outside above allowance to be discussed with sponsor prior to enrolling"
NCT03157089,Exclusion,"Previous or concomitant malignancies at other sites than the lung, except: Effectively treated non-melanoma skin cancers; Effectively treated carcinoma in situ of the cervix; Effectively treated ductal carcinoma in situ; Other effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured."
NCT01831089,Inclusion,Patients with a histologically/cytologically confirmed diagnosis of advanced and/or unresectable disease of any of the following tumors: Breast cancer Epithelial ovarian cancer or gynecological cancer Head and neck squamous cell carcinoma Non-small cell lung cancer Small cell lung cancer Platinum-refractory germ-cell tumors. Adenocarcinoma or carcinoma of unknown primary site
NCT01945775,Exclusion,Prior malignancy except for any of the following: Prior BRCA-associated cancer as long as there is no current evidence of the cancer Carcinoma in situ or non-melanoma skin cancer A cancer diagnosed and definitively treated ≥ 5 years before randomization with no subsequent evidence of recurrence
NCT04902885,Inclusion,"Histologically or cytologically confirmed extensive stage small cell lung cancer (ES-SCLC): Patients scheduled to receive carboplatin plus etoposide regimen: no prior systemic therapy (eg, chemotherapy or combined with immunotherapy); Patients scheduled to receive topotecan regimen: previously received 1/2 lines of chemotherapy or combined immunotherapy but not topotecan."
NCT01953913,Exclusion,"radiotherapy within 4 weeks prior to drug administration except as follows: palliative radiation to organs other than chest may be allowed up to 2 weeks prior to drug administration, and single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling."
NCT01953913,Exclusion,"childbearing potential (see Section 4.2.3)
who: are nursing or are pregnant or are not using an acceptable method of birth control, or do not plan to continue using this method throughout the trial and/or do not agree to submit to pregnancy testing required by this protocol"
NCT01139775,Inclusion,Phase 2 portion: Have a histological diagnosis of NSCLC other than predominantly squamous cell histology that is classified as Stage IV according to the 7th edition of the AJCC classification Eligible for a first line of palliative treatment with a platinum doublet Have archived or fresh tumor tissue (not cytology)
NCT03976375,Inclusion,Has progressive disease (PD) on treatment with one prior anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) monoclonal antibody (mAb) administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies. Retreatment with the same anti-PD-L1/PD-L1 mAb is acceptable in the overall course of treatment
NCT05205941,Exclusion,"Haematology, biochemistry or urinalysis results that are outside of the laboratory normal reference ranges and are either: considered clinically significant by the Principal Investigator or delegate; OR considered not clinically significant by the Principal Investigator or delegate but are also outside of Sponsor-approved clinically acceptable laboratory ranges"
NCT00935623,Exclusion,"Acute disease at the time of enrollment Acute disease is defined as the presence of a moderate or severe illness with or without fever; Challenge can be administered to persons with a minor illness, such as diarrhea or mild upper respiratory infection without fever (i.e., oral temperature < 38°C/100.4°F);"
NCT01500980,Exclusion,"History of: Sickle cell disease, sickle cell trait, or other hemoglobinopathies Splenectomy or functional asplenia Systemic anaphylaxis Gelatin allergy Severe allergic reactions to mosquito bites of study drugs Documented history of chronic or active neurologic disease Psoriasis or porphyria Ocular diseases including retinopathy or visual field defects"
NCT04201431,Inclusion,Answer all questions on the informed consent quiz correctly at first or second attempt Female volunteers are required to use a highly effective form of contraception during the course of the study as malaria challenge could pose a serious risk to both maternal health and the unborn foetus.
NCT02511054,Exclusion,"History of: Sickle cell disease, sickle cell trait, or other hemoglobinopathies Splenectomy or functional asplenia Systemic anaphylaxis Any allergic reactions to study drugs Documented history of chronic or active neurologic disease (including seizures, uncontrolled migraine headaches) Psoriasis or porphyria Ocular diseases including retinopathy or visual field defects"
NCT02773979,Exclusion,Active neoplastic disease*. Subjects with a history of malignancy may be included if treated by surgical excision or if treated by chemotherapy or radiation therapy and has been observed for a period that in the investigator's estimation provides a reasonable assurance of sustained cure (not less than 36 months).
NCT02773979,Exclusion,A screening ECG with abnormalities consistent with underlying heart disease.* Pathologic Q waves and significant ST-T wave changes; left ventricular hypertrophy; any non-sinus rhythm excluding isolated premature atrial or ventricular contractions; right or left bundle branch block; QT/QTc interval > 450 ms; or advanced (secondary or tertiary) A-V heart block.
NCT02773979,Exclusion,"Is using or intends to use a medication that is cross-reactive with CQ** or atovaquone and proguanil, such as cimetidine or metoclopramide, during the study period. Antacids and kaolin can be administered at least 4 hours from intake of chloroquine. Does not apply to infectivity controls"
NCT00666380,Exclusion,"Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or abnormal baseline laboratory screening tests ALT above normal range Creatinine above normal range Hemoglobin below normal range Platelet count below normal range Total white cell count below normal range"
NCT05095272,Exclusion,Vital signs taken after 5 minutes of resting in seated or supine position that fall outside the following ranges: Systolic blood pressure <=90 mm Hg or >=140 mm Hg. Diastolic blood pressure <=50 mm Hg or >=90 mm Hg. Heart rate <=40 bpm or >=100 bpm.
NCT04327310,Exclusion,"Abnormal vital signs at Screening (supine and standing) and on Day 1 (Parts A and C) or pre-inoculation on Day 8 (Part B) (supine), defined as any of the following: Systolic blood pressure <90 or >140 mmHg. Diastolic blood pressure <40 or >90 mmHg. Pulse rate <40 or >100 bpm."
NCT06069544,Exclusion,"The following diseases associated with immune dysregulation: Primary immunodeficiencies. History of solid organ or bone marrow transplantation. Asplenia: any condition resulting in the absence of a functional spleen. Currently existing or history of autoimmune disease including and not limited to thyroid autoimmune disease, multiple sclerosis, psoriasis, etc."
NCT05581641,Exclusion,"The following diseases associated with immune dysregulation: Primary immunodeficiencies. History of solid organ or bone marrow transplantation. Asplenia: any condition resulting in the absence of a functional spleen. Currently existing or history of autoimmune disease including and not limited to thyroid autoimmune disease, multiple sclerosis, psoriasis, etc."
NCT01713621,Inclusion,"Presence of mono-infection of P. falciparum confirmed by: Fever, as defined by axillary temperature ≥ 37.5°C or oral/rectal/tympanic temperature ≥ 38°C, or history of fever in the previous 24 hours (history of fever must be documented) and, Microscopically confirmed parasite infection: 1,000 to 75,000 asexual parasite count/µL blood."
NCT00541385,Inclusion,"Presence of acute uncomplicated P. falciparum mono-infection confirmed by: Fever, as defined by axillary temperature ≥37.5°C or oral/tympanic/rectal temperature ≥38°C, or documented history of fever in the previous 24 hours and, Positive microscopy of P. falciparum with parasite density between 1,000 and 200,000 asexual parasite count/µl of blood."
NCT06473662,Exclusion,"History of diabetic ketoacidosis requiring hospitalization within 6 months prior to enrolment, case of proliferative retinopathy or advanced neuropathy Subject having any of the following laboratory results at screening Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73
m2 Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) >3 times of upper limit normal"
NCT03555994,Exclusion,Significant hepatic disease (except for NASH or nonalcoholic fatty liver disease without portal hypertension or cirrhosis) and/or subjects with any of the following results at screening: Aspartate transaminase (AST) ≥ 3 × upper limit of normal (ULN) Alanine transaminase (ALT) ≥ 3 × ULN Total bilirubin ≥ 2 × ULN
NCT05369065,Exclusion,"Hepatic decompensation defined as the presence of any of the following: Serum albumin less than 3.5 g/dL International normalization ratio (INR) greater than 1.4 (unless due to therapeutic anticoagulants) Total bilirubin greater than 2 mg/dL with the exception of Gilbert syndrome History of esophageal varices, ascites, or hepatic encephalopathy"
NCT01018017,Exclusion,"Renal or liver impairment, defined as: Serum creatinine level of ≥ 1.4 mg/dL for females and ≥ 1.5 mg/dL for males AST and ALT ≥ 2xULN alkaline phosphatase and bilirubin > 1.5xULN (an isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin is <35%)"
NCT03310749,Exclusion,Subjects who show one of the following results at screening test: Exceeds 1.5 times the upper limit of the normal range of blood AST (SGOT) and ALT (SGPT) The creatinine clearance calculated by Cockcroft-Gault equation is below 80 mL/min. QTc > 450 ms in ECG or clinically significant abnormal rhythm
NCT02512523,Inclusion,"Patient has adequate renal and hepatic function at screening as defined by the following clinical chemistry results: (male) Serum creatinine <1.5 × upper limit of normal (ULN), (female) Serum creatinine <1.4 × upper limit of normal (ULN), Serum alanine aminotransferase <2.5 × ULN Serum aspartate aminotransferase <2.5 × ULN"
NCT00320021,Inclusion,Patients with diagnosis of diabetic nephropathy as defined by Serum Creatinine <=2.0 mg/dL at weeks -2 and -1 (PYR-205) Serum Creatinine >2.0 mg/dL but <=3.5 mg/dL at weeks -2 and -1 (PYR-207) Urinary albumin excretion >=300 mg/24 hours at week -2 No other known or suspected etiology for nephropathy
NCT02227303,Exclusion,Subject has any of the following medical conditions: active heart disease uncontrolled high blood pressure (≥ 140/90 mmHg) renal or hepatic impairment/disease Type I diabetes bipolar disorder active psychiatric disease Parkinson's disease unstable thyroid disease immune disorder (such as HIV/AIDS) any medical condition deemed exclusionary by the Principal Investigator (PI)
NCT05363761,Exclusion,"Hepatic decompensation defined as the presence of any of the following: Serum albumin less than 3.5 g/dL International normalization ratio (INR) greater than 1.4 (unless due to therapeutic anticoagulants) Total bilirubin greater than 2 mg/dL with the exception of Gilbert syndrome History of esophageal varices, ascites, or hepatic encephalopathy"
NCT05158244,Exclusion,"Participants with ANY of the following abnormalities in clinical laboratory tests: *AST or ALT level ≥1.5x ULN; Total bilirubin level ≥1.5x ULN; TSH> ULN; Fasting C-peptide <0.8 ng/mL; Serum calcitonin > ULN; Amylase > ULN; Lipase > ULN; eGFR <60 mL/min/1.73m2
(per MDRD equation); FPG >270 mg/dL"
NCT03217591,Exclusion,"Patient has clinically active, symptomatic, or unstable coronary artery or heart disease within the 3 months before the Screening Visit, defined as 1 of the following: Hospitalization for myocardial infarction (MI), unstable angina, or heart failure New-onset angina with positive functional study or coronary angiogram revealing stenosis Coronary revascularization procedure"
NCT03157089,Exclusion,"Previous or concomitant malignancies at other sites than the lung, except: Effectively treated non-melanoma skin cancers; Effectively treated carcinoma in situ of the cervix; Effectively treated ductal carcinoma in situ; Other effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured."
NCT01139775,Inclusion,Phase 2 portion: Have a histological diagnosis of NSCLC other than predominantly squamous cell histology that is classified as Stage IV according to the 7th edition of the AJCC classification Eligible for a first line of palliative treatment with a platinum doublet Have archived or fresh tumor tissue (not cytology)
NCT03976375,Inclusion,Has progressive disease (PD) on treatment with one prior anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) monoclonal antibody (mAb) administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies. Retreatment with the same anti-PD-L1/PD-L1 mAb is acceptable in the overall course of treatment
NCT02773979,Exclusion,A screening ECG with abnormalities consistent with underlying heart disease.* Pathologic Q waves and significant ST-T wave changes; left ventricular hypertrophy; any non-sinus rhythm excluding isolated premature atrial or ventricular contractions; right or left bundle branch block; QT/QTc interval > 450 ms; or advanced (secondary or tertiary) A-V heart block.
NCT02083380,Inclusion,"Presence of mono-infection of P. falciparum with: Fever, as defined by axillary temperature ≥ 37.5°C or oral/rectal/tympanic temperature ≥ 38°C, or history of fever in the previous 24 hours (history of fever must be documented) and, Microscopically confirmed parasite infection, in range 1,000 to 100,000 asexual parasites /µL of blood."
NCT00298610,Exclusion,"Laboratory evidence or history of significant cardiovascular, liver or renal functional abnormality, which in the opinion of the investigator would place them at increased risk.
Specifically, the following will serve as exclusionary lab values: Creatinine >1.4 x ULN (>2.0 mg/dL) Glucose <LLN (65mg/dL) AST, ALT >3x ULN (120 U/L)"
NCT04327310,Exclusion,"Abnormal vital signs at Screening (supine and standing) and on Day 1 (Parts A and C) or pre-inoculation on Day 8 (Part B) (supine), defined as any of the following: Systolic blood pressure <90 or >140 mmHg. Diastolic blood pressure <40 or >90 mmHg. Pulse rate <40 or >100 bpm."
NCT01713621,Inclusion,"Presence of mono-infection of P. falciparum confirmed by: Fever, as defined by axillary temperature ≥ 37.5°C or oral/rectal/tympanic temperature ≥ 38°C, or history of fever in the previous 24 hours (history of fever must be documented) and, Microscopically confirmed parasite infection: 1,000 to 75,000 asexual parasite count/µL blood."
NCT00541385,Inclusion,"Presence of acute uncomplicated P. falciparum mono-infection confirmed by: Fever, as defined by axillary temperature ≥37.5°C or oral/tympanic/rectal temperature ≥38°C, or documented history of fever in the previous 24 hours and, Positive microscopy of P. falciparum with parasite density between 1,000 and 200,000 asexual parasite count/µl of blood."
NCT03555994,Exclusion,"Any subject who has received any of the following medications prior to the start of the study: Herbal preparations or drugs licensed for control of body weight or appetite (eg, orlistat, bupropion naltrexone, phentermine-topiramate, phentermine, lorcaserin) Opiates, domperidone, metoclopramide or other drugs known to alter gastric emptying Glucagon Warfarin"
NCT04373265,Exclusion,"Treated with the following prior to the first dose of relacorilant: Any investigational product, systemic anticancer therapy, or radiation therapy within 21 days Antibodies or anticancer vaccines within 60 days Mifepristone or other GR antagonists within 5 half-lives of these medications Adrenostatic medications within 5 half-lives of these medications"
NCT02089126,Exclusion,"Patients who are continuously taking the following drugs for 2 weeks or more at Visit 1 (screening), or need to take them continuously and repeatedly cyclosporin, sirolimus, tacrolimus, nicotinic acid (≥1500mg/day), isotretinoin Strong CYP3A4 inducers: rifampicin (rifampin), phenytoin, carbamazepine, rifabutin, phenobarbital warfarin, dicoumarin, digoxin systemic glucocorticoids"
NCT02974816,Inclusion,"If female is of childbearing potential, is practicing one of the following methods of birth control (and will continue through the duration of the study): Condoms, sponge, diaphragm, or intrauterine device; Oral or parenteral contraceptives for 3 months prior to screening visit; Vasectomized partner; Total abstinence from sexual intercourse"
NCT00601250,Exclusion,"Pre-menopausal women who: are nursing or pregnant, or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial."
NCT03091712,Inclusion,"If female is of childbearing potential, is practicing one of the following methods of birth control (and will continue through the duration of the study): Condoms, sponge, diaphragm, or intrauterine device; Oral or parenteral contraceptives for 3 months prior to screening visit; Vasectomized partner; Total abstinence from sexual intercourse"
NCT02954601,Exclusion,"Any clinically significant ECG abnormality at Screening or cardiovascular disease.
Clinically significant cardiovascular disease will include: History of stroke, transient ischemic attack, or myocardial infarction within 6 months prior to Screening, History of or currently have New York Heart Associate Class II-IV heart failure prior to Screening, or"
NCT04515849,Exclusion,Significant hepatic disease (except for non-alcoholic steatohepatitis or nonalcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results: Aspartate transaminase (AST) ≥ 3 × upper limit of normal (ULN) Alanine transaminase (ALT) ≥ 3 × ULN Total bilirubin ≥ 2 × ULN
NCT00879970,Inclusion,"Age ≥ 55 years and evidence of subclinical vascular disease defined as ≥1 of: microalbuminuria or proteinuria history of treated or untreated hypertension with left ventricular hypertrophy by electrocardiogram (ECG) or echocardiogram 50% stenosis on any imaging of coronary, carotid or lower extremity arteries ankle/brachial index <0.9 OR"
NCT06151964,Exclusion,Use of any of the following medicinal products: Use of systemic corticosteroids within 28 days prior to screening. Use of compounds known to prolong the QTc interval. Use of any herbal preparations or medicinal products licensed for control of body weight or appetite within 3 months prior to screening.
NCT01677299,Exclusion,"Has a clinically significant medical condition that could potentially affect study participation and/or personal well-being, as judged by the investigator, including but not limited to the following conditions: Hepatic disease Renal disease Gastrointestinal disease Endocrine disorder except diabetes Cardiovascular disease Seizure disorder Organ transplantation Chronic infection"
NCT00625859,Exclusion,"Cardiac system Subject has a history of clinically significant cardiac rhythm disorder or QTc interval ³450 milliseconds at Screening. Subject has history of ischemic heart disease, including stable/unstable angina or acute myocardial infarction. Uncontrolled hypertension with systolic blood pressure >140mm Hg and diastolic blood pressure >90mm Hg."
NCT03745937,Exclusion,Significant hepatic disease (except for nonalcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results at screening: Aspartate transaminase (AST) >= 3 × ULN Alanine transaminase (ALT) >= 3 × ULN Total bilirubin (TBL) >= 2 × ULN
NCT03138356,Inclusion,"For inclusion in the study subjects should fulfill the following criteria: Provision of signed and dated, written informed consent prior to any study specific procedures. Healthy male and/or female subjects aged 18 to 55 years with suitable veins for cannulation or repeated venipuncture. Female subject must either:"
NCT04150107,Inclusion,"Females who are not of childbearing potential are defined as: post-menopausal (defined as at least 12 months with no menses in women ≥45 years of age) or has had a hysterectomy and/or bilateral oophorectomy, or had bilateral tubal ligation or occlusion at least 6 weeks prior to Screening"
NCT03387683,Exclusion,"Any of the following cardiovascular diseases known within 3 months prior to signing the consent at enrolment: Atrial fibrillation, or other unstable or severe arrhythmia affecting heart function Unstable heart failure or any heart failure with NYHA class III and IV Significant valvular disease Significant peripheral artery disease"
NCT03550378,Exclusion,Significant hepatic disease (except for non-alcoholic steatohepatitis or nonalcoholic fatty liver disease without portal hypertension or cirrhosis) and/or participants with any of the following results: Aspartate transaminase (AST) ≥ 3 × upper limit of normal (ULN) Alanine transaminase (ALT) ≥ 3 × ULN Total bilirubin ≥ 2 × ULN
NCT02561078,Inclusion,"Current TDD >200 but ≤600 units of non U-500R insulin (MDI or CSII) and/or U-500R by MDI with syringe and vial for ≥3 months at entry. If TDD of U-500R and other insulins are combined, then insulin other than U-500R not to exceed 25% of TDD."
NCT02791490,Exclusion,"Has human immunodeficiency virus (HIV) with AIDS related complications, or has not been on a stable anti-retroviral regimen for >6 months, or has progressive disease, or using agents associated with glucose intolerance such as nucleoside reverse transcriptase inhibitors (NRTIs) such as azidothymidine (AZT), didanosine (ddI), and stavudine (d4T)."
NCT01551446,Exclusion,"Recently active cardiovascular disease defined as: Unstable angina pectoris within 12 weeks before Study Day 1; Myocardial infarction, coronary artery bypass graft surgery, or percutaneous transluminal coronary angioplasty/stent within 12 weeks before Study Day 1; Cerebrovascular accident, including transient ischemic attack within 12 weeks before Study Day 1;"
NCT01582451,Exclusion,Lipid-lowering medication: Are using or have used any of the following: niacin preparations as a lipid-lowering medication and/or bile acid sequestrants within 90 days prior to screening or lipid-lowering medication at a dose that has not been stable for at least 90 days prior to screening
NCT02079805,Exclusion,"Past or current history of any of the following cardiovascular diseases. Cardiac valve stenosis Angina pectoris requiring medication Congestive cardiac failure requiring medication Arrhythmia requiring medication (e.g., paroxysmal atrial fibrillation, severe bradycardia, torsade de pointes, and ventricular fibrillation) Arteriosclerosis obliterans with intermittent claudication or other symptoms"
NCT00734253,Inclusion,"At the Qualifying Visit (only applies to those patients who enter into the Optional Run-in Period), the following eligibility parameters must be met in order to be randomized: A SCr measurement within 25% of the SCr measurement at the Screening Visit; and A 24-hour urine collection PCR ≥600 mg/g."
NCT04350463,Exclusion,"Subject has previous SARS-CoV-2 infection either suspected or confirmed within 4 weeks prior to screening. Acute symptoms must have resolved and based on Investigator assessment in consultation with the Medical Monitor, there are no sequelae that would place the subject at a higher risk of receiving investigational treatment."
NCT02358473,Exclusion,"History of second primary cancer within the past 5 years, with the exception of: Curatively resected non-melanomatous skin cancer; Curatively treated cervical intraepithelial neoplasia or prostate carcinoma with current prostate specific antigen (PSA) < 0.01 ng/mL; or Curatively treated ductal carcinoma in situ of the breast;"
NCT02082210,Exclusion,"For Part B4 (non-small cell lung cancer) only: The participant has radiologically documented evidence of major blood vessel invasion or encasement by cancer Participants with a history of gross hemoptysis within 2 months prior to study treatment The participant has radiographic evidence of intratumor cavitation, regardless of tumor histology"
NCT01945775,Exclusion,Prior malignancy except for any of the following: Prior BRCA-associated cancer as long as there is no current evidence of the cancer Carcinoma in situ or non-melanoma skin cancer A cancer diagnosed and definitively treated ≥ 5 years before randomization with no subsequent evidence of recurrence
NCT01853878,Exclusion,"The patient has received any anti-cancer specific treatment, including radiotherapy, immunotherapy, hormonal therapy, chemotherapy or neo-adjuvant chemotherapy, except for: Administration of adjuvant platinum-based doublet chemotherapy for the treatment of the current NSCLC allowed between surgery and randomization. Treatment of previous malignancies as allowed by the protocol."
NCT04902885,Inclusion,"Histologically or cytologically confirmed extensive stage small cell lung cancer (ES-SCLC): Patients scheduled to receive carboplatin plus etoposide regimen: no prior systemic therapy (eg, chemotherapy or combined with immunotherapy); Patients scheduled to receive topotecan regimen: previously received 1/2 lines of chemotherapy or combined immunotherapy but not topotecan."
NCT01953913,Exclusion,"radiotherapy within 4 weeks prior to drug administration except as follows: palliative radiation to organs other than chest may be allowed up to 2 weeks prior to drug administration, and single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor prior to enrolling."
NCT01953913,Exclusion,"childbearing potential (see Section 4.2.3)
who: are nursing or are pregnant or are not using an acceptable method of birth control, or do not plan to continue using this method throughout the trial and/or do not agree to submit to pregnancy testing required by this protocol"
NCT03310619,Exclusion,Prior treatment with the combination agent from the assigned arm: Anti PD-1 or PD-L1 (Arm A and E) CC-122 (Arm B) CC-220 (Arm C) Prior treatment with ibrutinib is not exclusionary for subjects on any study arm Anti LAG-3 targeted agent (Arm E) CC-99282 (Arm F)
NCT01877083,Inclusion,"Adequate bone marrow function, defined as: Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L (greater than or equal to 1500/mm^3) Hemoglobin (Hb) greater than or equal 8.5 g/dL Platelet count greater than or equal 75 x 10^9/L (greater than or equal 75,000/mm^3)"
NCT02020577,Exclusion,Female patients of childbearing potential who: are nursing or are pregnant or are not using an acceptable method of birth control or do not plan to continue using this method throughout the study and/or do not agree to submit to pregnancy testing required by this protocol.
NCT05205941,Exclusion,"Haematology, biochemistry or urinalysis results that are outside of the laboratory normal reference ranges and are either: considered clinically significant by the Principal Investigator or delegate; OR considered not clinically significant by the Principal Investigator or delegate but are also outside of Sponsor-approved clinically acceptable laboratory ranges"
NCT04201431,Inclusion,Answer all questions on the informed consent quiz correctly at first or second attempt Female volunteers are required to use a highly effective form of contraception during the course of the study as malaria challenge could pose a serious risk to both maternal health and the unborn foetus.
NCT02511054,Exclusion,"History of: Sickle cell disease, sickle cell trait, or other hemoglobinopathies Splenectomy or functional asplenia Systemic anaphylaxis Any allergic reactions to study drugs Documented history of chronic or active neurologic disease (including seizures, uncontrolled migraine headaches) Psoriasis or porphyria Ocular diseases including retinopathy or visual field defects"
NCT01434381,Exclusion,"Severe asthma.
This will be defined as: Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past 2 years, or that requires the use of oral or parenteral corticosteroids. Clinically significant reactive airway disease that does not respond to bronchodilators."
NCT07060508,Inclusion,Females of childbearing potential must be willing to use reliable contraception from 21 days prior to study Day 0 through the final study visit as described below. Reliable methods of birth control include 1 of the following: confirmed pharmacologic contraceptives via parenteral delivery or intrauterine or implantable device.
NCT02554799,Inclusion,Females must be of non-childbearing potential: Natural (spontaneous) post-menopausal defined (amenorrheic for at least 12 months without an alternative medical cause with a screening follicle stimulating hormone level >25IU/L (for post-menopause). Premenopausal with irreversible surgical sterilization by hysterectomy and/or bilateral oophorectomy or salpingectomy at least 6 months before screening
NCT02773979,Exclusion,Active neoplastic disease*. Subjects with a history of malignancy may be included if treated by surgical excision or if treated by chemotherapy or radiation therapy and has been observed for a period that in the investigator's estimation provides a reasonable assurance of sustained cure (not less than 36 months).
NCT02773979,Exclusion,"Is using or intends to use a medication that is cross-reactive with CQ** or atovaquone and proguanil, such as cimetidine or metoclopramide, during the study period. Antacids and kaolin can be administered at least 4 hours from intake of chloroquine. Does not apply to infectivity controls"
NCT00666380,Exclusion,"Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or abnormal baseline laboratory screening tests ALT above normal range Creatinine above normal range Hemoglobin below normal range Platelet count below normal range Total white cell count below normal range"
NCT00487916,Exclusion,"Severe asthma.
This will be defined as: Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past two years or that requires the use of oral or parenteral corticosteroids. Clinically significant reactive airway disease that does not respond to bronchodilators."
NCT05095272,Exclusion,Vital signs taken after 5 minutes of resting in seated or supine position that fall outside the following ranges: Systolic blood pressure <=90 mm Hg or >=140 mm Hg. Diastolic blood pressure <=50 mm Hg or >=90 mm Hg. Heart rate <=40 bpm or >=100 bpm.
NCT02458092,Inclusion,• A male or non-lactating female 18 to 50 years of age (inclusive) at the time of screening Free of significant health problems as established by medical history and clinical examination before entering into the study Available to participate for duration of study (approximately seven months)
NCT00414336,Exclusion,"Severe asthma.
This will be defined as: Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past two years or that requires the use of oral or parenteral corticosteroids; Clinically significant reactive airway disease that does not respond to bronchodilators."
NCT06069544,Exclusion,"The following diseases associated with immune dysregulation: Primary immunodeficiencies. History of solid organ or bone marrow transplantation. Asplenia: any condition resulting in the absence of a functional spleen. Currently existing or history of autoimmune disease including and not limited to thyroid autoimmune disease, multiple sclerosis, psoriasis, etc."
NCT05581641,Exclusion,"The following diseases associated with immune dysregulation: Primary immunodeficiencies. History of solid organ or bone marrow transplantation. Asplenia: any condition resulting in the absence of a functional spleen. Currently existing or history of autoimmune disease including and not limited to thyroid autoimmune disease, multiple sclerosis, psoriasis, etc."
NCT00889616,Exclusion,"Severe asthma.
This will be defined as: Asthma that is unstable or required emergent care, urgent care, hospitalization or intubation during the past 2 years, or that requires the use of oral or parenteral corticosteroids Clinically significant reactive airway disease that does not respond to bronchodilators"
